WO2010074192A1 - 抗lgr7抗体を用いる癌の診断および治療 - Google Patents
抗lgr7抗体を用いる癌の診断および治療 Download PDFInfo
- Publication number
- WO2010074192A1 WO2010074192A1 PCT/JP2009/071524 JP2009071524W WO2010074192A1 WO 2010074192 A1 WO2010074192 A1 WO 2010074192A1 JP 2009071524 W JP2009071524 W JP 2009071524W WO 2010074192 A1 WO2010074192 A1 WO 2010074192A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- seq
- amino acid
- acid sequence
- chain
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Definitions
- the present invention relates to an antibody that binds to LGR7 protein, a cancer diagnostic method, a therapeutic method, and an anticancer agent.
- the LGR7 molecule is a protein encoded by the ENSG00000171509 gene of Ensembl ⁇ ID ⁇ on human chromosome 4q32, and the LGR family of hormone receptor family of G protein-coupled seven-fold membrane-bound proteins (Leucine-rich GPCR family, hereinafter referred to as LGR family) It is a molecule that has been elucidated from the characteristics of its amino acid sequence (Non-patent Document 1). In addition, it is registered as NM_021634 / NP_067647 by RefSeq. A sequence in which the 70th amino acid is changed from Leu to Met has also been reported (Patent Document 1).
- LGR7.1 (AY899848.1) has an exon 6a inserted between exons 6 and 7, and exon 15a inserted between exons 15 and 16.
- LGR7.2 (AY899849.1) has a gene structure lacking exons 12 and 13.
- LGR7.10 (AY899850.1) is missing exon 3.
- the LGR family members are divided into three groups, the first group is the hormone receptor of FSHR (LGR1), LHCGR (LGR2) or TSHR (LGR3), the second group is LGR4, LGR5 or LGR6 with unknown ligand, the third group is LGR7 or LGR8 having relaxin, insulin-like peptide 3 (INSL3) or the like as a ligand (Non-patent Document 2).
- LGR1 hormone receptor of FSHR
- LGR2 LHCGR
- LGR3 TSHR
- LGR4 LGR5 or LGR6 with unknown ligand
- LGR7 or LGR8 having relaxin, insulin-like peptide 3 (INSL3) or the like as a ligand
- Non-patent Document 2 two heterologous peptides are ligands, and it is known to transmit signals mainly via cAMP into cells.
- the LGR family has a structure consisting of a seven-transmembrane protein region and an extracellular region with a long N-terminus, and a leucine-rich region consisting of about 25 amino acid residues in the extracellular region (leucine-rich repeat: LRR). 9-17).
- LGR7 has 10 LRRs (Non-Patent Document 1).
- an LDL-A domain that is not found in other LGR family molecules is present at the N-terminus immediately before LRR (Non-patent Document 3). It has been reported that LDL-A is required for signal transduction and is also involved in LGR7 trafficking (Non-patent Document 4).
- Non-Patent Document 5 Relaxin is known as a ligand that binds to LGR7. In humans, relaxin 2 and relaxin 3 are available, but relaxin 2 has a higher binding ability and functions as a ligand for LGR7 in vivo. (Non-Patent Documents 6 and 7).
- Non-patent Document 8 there is a report on the relationship with thyroid cancer (Thyroid carcinoma) and prostate cancer (prostate cancer) (Non-patent Document 8).
- prostate cancer it has been reported that the growth of androgen-independent growth is promoted in the prostate cancer cell line LNCaP into which p53 in which the 273th amino acid R is mutated to H is introduced (Non-patent Document 9).
- the increase in H2 relaxin in these cells suggests that H2 relaxin is expressed and involved in prostate cancer progression, and p53 of R273H directly binds to the promoter of H2 relaxin, and through the androgen receptor It has been shown to induce expression.
- LGR7 LNCaP into which p53 in which the 273th amino acid R is mutated to H is introduced
- Non-patent Documents 10 and 11 Sugiyama et al. Show that response rate to chemotherapy including cisplatin and taxane compounds, which are standard treatments, is 72.5% for serous adenocarcinoma and 11.1% for clear cell adenocarcinoma. (Non-Patent Document 10).
- the number of patients with clear cell adenocarcinoma has increased in recent years, and according to the Nissan Women's Journal Vol. 57, No. 11, 1711 (2005), clear cell adenocarcinoma accounts for 22% of all ovarian cancers in Japan. Has been.
- An object of the present invention is to provide a novel antibody that binds to the LGR7 protein, a novel method for diagnosing cancer, a novel method for treating cancer, a novel cell growth inhibitor, and an anticancer agent.
- LGR7 is a clear cell adenocarcinoma cell of ovarian cancer and highly expresses not only its gene but also its protein. Until now, it has not been reported that LGR7 is deeply related to only one ovarian cancer, clear cell adenocarcinoma. In addition, the present inventors made a monoclonal antibody against LGR7 protein. Furthermore, the present inventors measured the antibody-dependent cell-mediated cytotoxicity (ADCC) activity of the anti-LGR7 antibody, and found that the anti-LGR7 antibody has ADCC activity against LGR7-expressing cells. It was.
- ADCC antibody-dependent cell-mediated cytotoxicity
- the anti-LGR7 antibody has CDC activity against LGR7-expressing cells. Furthermore, when the anti-LGR7 antibody was administered to a xenograft tumor model mouse, it was revealed that it exhibited a tumor reducing effect. Based on the above findings, the present inventors have found that the anti-LGR7 antibody is effective for the diagnosis, prevention and treatment of primary or metastatic ovarian clear cell adenocarcinoma and completed the present invention. . More specifically, the present inventors have found that anti-LGR7 antibody is useful as a tool for treatment or diagnosis of cancers in which LGR7 expression is enhanced, including ovarian clear cell adenocarcinoma. As a result, the present invention has been completed.
- the present invention provides an antibody that binds to the LGR7 protein. Furthermore, the present invention provides an antibody that binds to LGR7 protein and has cytotoxic activity against cells that express LGR7 protein. Preferably, the cytotoxic activity is ADCC activity. The present invention also provides an anti-LGR7 antibody conjugated with a cytotoxic substance.
- the present invention provides a pharmaceutical composition containing an antibody that binds to LGR7 protein as an active ingredient.
- the present invention also provides a cytostatic agent containing an antibody that binds to LGR7 protein as an active ingredient.
- the present invention also provides an anticancer agent containing an antibody that binds to LGR7 protein as an active ingredient.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an antibody that binds to LGR7 protein and a pharmaceutically acceptable carrier. More specifically, the following [1] to [23] are provided.
- the antibody according to [1], wherein the cell growth inhibitory activity is cytotoxic activity.
- the antibody according to [2], wherein the cytotoxic activity is antibody-dependent cytotoxic activity.
- the antibody according to [2], wherein the cytotoxic activity is complement-dependent cytotoxic activity.
- [6] The antibody according to [5], which is an antibody having an internalizing activity.
- [8] The antibody according to [7], wherein the cancer cell is a clear cell of ovarian cancer.
- a pharmaceutical composition comprising the antibody according to any one of [1] to [12] as an active ingredient.
- a cell growth inhibitor containing the antibody according to any one of [1] to [12] as an active ingredient.
- An anticancer agent comprising the antibody according to any one of [1] to [12] as an active ingredient.
- the anticancer agent according to [15], wherein the cancer to be treated is ovarian cancer.
- the anticancer agent according to [16], wherein the ovarian cancer is clear cell adenocarcinoma.
- a method for diagnosing cancer comprising detecting LGR7 protein or a gene encoding LGR7 protein.
- a method for diagnosing cancer comprising detecting LGR7 protein.
- the diagnostic method according to [19], wherein the LGR7 protein is detected using an antibody that binds to the LGR7 protein.
- a method for diagnosing cancer comprising the following steps; (A) providing a sample collected from the subject; (B) A step of detecting the LGR7 protein contained in the sample of (a) using an antibody that binds to the LGR7 protein. [22] A method for diagnosing cancer comprising the following steps; (A) a step of administering an antibody having a binding activity to LGR7 protein and labeled with a radioisotope to a subject; (B) detecting the accumulation of the radioisotope. [23] The diagnostic method according to any one of [18] to [22], wherein the cancer to be diagnosed is ovarian cancer. [24] The diagnostic method according to [23], wherein the ovarian cancer is clear cell adenocarcinoma.
- the histological breakdown of 10 cases of ovarian cancer is 4 clear cell carcinomas, 2 serous adenocarcinomas, 3 endometrioid adenocarcinomas, 1 carcinosarcoma and 10 normal tissues, 4 fetal tissues, 4 types
- IGC International Genomics
- C clear cell adenocarcinoma
- E moss endometrial adenocarcinoma
- S serous adenocarcinomas
- M mucinous adenocarcinoma
- O other cancers
- B Benign serous cystadenoma of borderline malignancy JHOC-5
- MCAS MCAS
- RMG-1 RMUG-S
- TKY-nu are ovarian cancer cell lines, of which RMG-1 is a cell line derived from clear cell adenocarcinoma.
- LGR7 expression in HA-LGR7 / BaF3 # 48 and HA-LGR7 / DG44 # 24 is a photograph showing the results of WB detection using anti-HA antibody (HA-7) after SDS-PAGE electrophoresis of cell lysates is there.
- Each lane is Lane 1: BaF3, Lane 2: HA-LGR7 / BaF3 # 48, Lane 3: DG44, Lane 4: HA-LGR7 / DG44 # 24. It is a figure which shows the result of having measured the ADCC activity which used HA-LGR7 / DG44 as a target cell and NK92mFcR3 as an effector cell by Cr * release *.
- the solid line shows the result of the action of the biotinylated antibody, and the shaded peak shows the result of the reaction with the FITC-labeled anti-mouse antibody.
- the result of a medicinal effect test using mouse xenograft model is shown.
- the graph shows the change in tumor volume by antibody administration against the number of days after tumor transplantation.
- the solid line is the result of the negative control PBS administration group
- the square broken line is the result of the antibody FTKODA23 ⁇ 10mg / kg ⁇ administration group
- the triangle broken line is the result of the antibody FTKODA23 ⁇ 2mg / kg ⁇ administration group.
- LGR7 is a protein that is a seven-transmembrane LGR family member.
- the amino acid sequence of human LGR7 and the gene sequence encoding the same are disclosed in NCBI accession numbers NP_067647 (SEQ ID NO: 1) and NM_021634 (SEQ ID NO: 2), respectively.
- LGR7 used in the present invention may be a splicing variant or mutant.
- LGR7 protein is meant to include both full-length protein and fragments thereof.
- the fragment is a polypeptide containing an arbitrary region of the LGR7 protein, and may not have the function of the natural LGR7 protein. Examples of fragments include fragments containing the extracellular region of LGR7 protein.
- the extracellular region of LGR7 protein corresponds to the amino acid sequence of SEQ ID NO: 1, positions 1-404, 462-485, 549-581, and 648-661.
- the transmembrane region is 405-427, 439-461, 486-508, 529-548, 582-604, 625-647, and 662-681 in the amino acid sequence of SEQ ID NO: 1. Equivalent to.
- anti-LGR7 antibody used in the present invention may be bound to the LGR7 protein, and its origin, type, shape and the like are not limited. Specifically, known antibodies such as non-human animal antibodies (eg, mouse antibodies, rat antibodies, camel antibodies), human antibodies, chimeric antibodies, and humanized antibodies can be used. In the present invention, monoclonal or polyclonal antibodies can be used as antibodies, but monoclonal antibodies are preferred.
- the binding of the antibody to the LGR7 protein is preferably specific binding.
- the anti-LGR7 antibody used in the present invention is an antibody that recognizes human LGR7, it may be an antibody that specifically recognizes human LGR7, or LGR7 derived from another animal (for example, mouse LGR7). It may be an antibody that recognizes simultaneously.
- the anti-LGR7 antibody used in the present invention can be obtained as a polyclonal or monoclonal antibody using known means.
- the anti-LGR7 antibody used in the present invention is particularly preferably a mammal-derived monoclonal antibody.
- Mammal-derived monoclonal antibodies include those produced by hybridomas and those produced by hosts transformed with expression vectors containing antibody genes by genetic engineering techniques.
- Monoclonal antibody-producing hybridomas can be basically produced using known techniques as follows. First, LGR7 protein is used as a sensitizing antigen, and this is immunized according to a normal immunization method. Immune cells obtained from an immunized animal are fused with a known parent cell by a conventional cell fusion method to obtain a hybridoma. Furthermore, from this hybridoma, a hybridoma producing an anti-LGR7 antibody can be selected by screening cells producing the target antibody by a usual screening method.
- an LGR7 protein used as a sensitizing antigen for antibody acquisition can be obtained.
- the base sequence of LGR7 gene is disclosed in NCBI registration number NM — 021634 (SEQ ID NO: 2) and the like. That is, after inserting a gene sequence encoding LGR7 into a known expression vector and transforming an appropriate host cell, the target human LGR7 protein is purified from the host cell or culture supernatant by a known method. it can. Purified natural LGR7 protein can also be used as well.
- a fusion protein obtained by fusing a desired partial polypeptide of LGR7 protein with a different polypeptide can also be used as an immunogen.
- an immunogen for example, an Fc fragment of an antibody, a peptide tag, or the like can be used.
- a vector that expresses the fusion protein can be prepared by fusing genes encoding two or more desired polypeptide fragments in-frame and inserting the fusion gene into an expression vector. The method for producing the fusion protein is described in Molecular® Cloning® 2nd® ed. (Sambrook, Jet et al., “Molecular® Cloning® 2nd® ed.,” 9.47-9.58, “Cold® Spring® Harbor® Lab.® press,” 1989).
- the LGR7 protein thus purified can be used as a sensitizing antigen used for immunization against mammals.
- a partial peptide of LGR7 can also be used as a sensitizing antigen.
- the following peptides can be used as the sensitizing antigen. Peptides obtained by chemical synthesis based on the amino acid sequence of human LGR7 Peptides obtained by integrating and expressing part of the LGR7 gene in an expression vector Peptides obtained by proteolytic degradation of LGR7 protein
- LGR7 used as a partial peptide are not limited.
- a preferred region can be selected from the amino acid sequence constituting the extracellular domain of LGR7 (positions 1-404, 462-485, 549-581, and 648-661 in the amino acid sequence of SEQ ID NO: 1).
- the number of amino acids constituting the peptide to be sensitized antigen is preferably at least 3 or more, for example, 5 or more, or 6 or more. More specifically, a peptide having 8 to 50, preferably 10 to 30 residues can be used as a sensitizing antigen.
- the mammal immunized with the sensitizing antigen is not particularly limited.
- an immunized animal in consideration of compatibility with a parent cell used for cell fusion.
- rodent animals are preferred as immunized animals. Specifically, mice, rats, hamsters, or rabbits can be used as immunized animals.
- monkeys and the like can be used as immunized animals.
- the above animals can be immunized with a sensitizing antigen.
- mammals can be immunized by injecting a sensitizing antigen intraperitoneally or subcutaneously. Specifically, the sensitizing antigen is administered to mammals several times every 4 to 21 days.
- the sensitizing antigen is diluted with PBS (Phosphate-Buffered Saline) or physiological saline at an appropriate dilution ratio and used for immunization.
- a sensitizing antigen can be administered with an adjuvant. For example, it can be mixed with Freund's complete adjuvant and emulsified to give a sensitizing antigen.
- An appropriate carrier can be used for immunization with the sensitizing antigen.
- a partial peptide having a small molecular weight is used as a sensitizing antigen, it is desirable to immunize the sensitizing antigen peptide by binding it to a carrier protein such as albumin or keyhole limpet hemocyanin.
- DNA immunization a vector DNA constructed in such a manner that a gene encoding an antigen protein (eg, SEQ ID NO: 2) can be expressed in an immunized animal is administered to the immunized animal, and the immunizing antigen is administered in vivo to the immunized animal. It is a method of giving immunostimulation by expressing in. Compared to general immunization methods that administer protein antigens, DNA immunization can be expected to have the following advantages. -Maintains the structure of membrane proteins like LGR7 and can provide immune stimulation-No need to purify immune antigens
- LGR7 has the structural feature of a seven-transmembrane three-dimensional structure, it was expected that it would be difficult to elicit an immune response while maintaining the naturally occurring structure in vivo. It is an unexpected result that a monoclonal antibody that binds to LGR7, which is a protein belonging to the LGR family, for which it was difficult to obtain antibodies, was actually obtained by DNA immunization because of such structural characteristics.
- DNA expressing LGR7 protein is first administered to an immunized animal.
- DNA encoding LGR7 can be synthesized by a known method such as PCR.
- the obtained DNA is inserted into an appropriate expression vector and administered to an immunized animal.
- the expression vector for example, a commercially available expression vector such as pcDNA3.1 can be used.
- a method of administering the vector to a living body a generally used method can be used.
- DNA immunization can be performed by implanting gold particles adsorbed with an expression vector into cells with a gene gun.
- immune cells are collected from the mammal and subjected to cell fusion.
- spleen cells can be used.
- Mammalian myeloma cells are used as cells to be fused with the above immune cells.
- the myeloma cell is preferably provided with an appropriate selection marker for screening.
- a selectable marker refers to a trait that can (or cannot) survive under certain culture conditions.
- Known selection markers include hypoxanthine-guanine-phosphoribosyltransferase deficiency (hereinafter abbreviated as HGPRT deficiency) or thymidine kinase deficiency (hereinafter abbreviated as TK deficiency).
- HGPRT deficiency hypoxanthine-guanine-phosphoribosyltransferase deficiency
- TK deficiency thymidine kinase deficiency
- Cells having HGPRT or TK deficiency have hypoxanthine-aminopterin-thymidine sensitivity (hereinafter abbreviated as HAT sensitivity).
- HGPRT-deficient and TK-deficient cells can be selected in media containing 6 thioguanine, 8 azaguanine (hereinafter abbreviated as 8AG), or 5 'bromodeoxyuridine, respectively.
- 8AG 8 azaguanine
- Normal cells die because they incorporate these pyrimidine analogs into the DNA, but cells deficient in these enzymes cannot survive these pyrimidine analogs and can survive in selective media.
- a selectable marker called G418 resistance confers resistance to 2-deoxystreptamine antibiotics (gentamicin analogs) with a neomycin resistance gene.
- Various myeloma cells suitable for cell fusion are known. For example, the following myeloma cells can be used for the production of the monoclonal antibody in the present invention.
- P3 P3x63Ag8.653
- P3x63Ag8U.1 Current Topics in Microbiology and Immunology (1978) 81, 1-7)
- NS-1 Kohler. G. and Milstein, C. Eur. J. Immunol. (1976) 6, 511-519
- MPC-11 Margulies. DH et al., Cell (1976) 8, 405-415
- SP2 / 0 Shulman, M. et al., Nature (1978) 276, 269-270
- FO de St. Groth, S. F. etal., J. Immunol.
- immune cells and myeloma cells according to known methods such as the method of Kohler and Milstein et al. (Kohler. Ler G. and Milstein, C., Methods Enzymol. (1981) 73, 3-46) And cell fusion.
- cell fusion can be carried out in a normal nutrient culture medium in the presence of a cell fusion promoter.
- a cell fusion promoter for example, polyethylene glycol (PEG), Sendai virus (HVJ) or the like can be used.
- an auxiliary agent such as dimethyl sulfoxide can be added as desired in order to increase the fusion efficiency.
- the usage ratio of immune cells and myeloma cells can be set arbitrarily.
- the number of immune cells is preferably 1 to 10 times that of myeloma cells.
- the culture solution used for cell fusion for example, RPMI1640 culture solution suitable for growth of myeloma cell line, MEM culture solution, and other normal culture solutions used for this type of cell culture can be used.
- serum supplements such as fetal calf serum (FCS) can be added to the culture medium.
- a predetermined amount of immune cells and myeloma cells are mixed well in a culture solution, and a target PEG (hybridoma) is formed by mixing a PEG solution preheated to about 37 ° C.
- a target PEG hybrida
- PEG having an average molecular weight of about 1000 to 6000 can be usually added at a concentration of 30 to 60% (w / v).
- cell fusion agents and the like that are undesirable for the growth of hybridomas are removed by sequentially adding the appropriate culture medium listed above, and then centrifuging to remove the supernatant.
- the hybridoma obtained in this manner can be selected by using a selective culture solution corresponding to the selection marker possessed by the myeloma used for cell fusion.
- a selective culture solution corresponding to the selection marker possessed by the myeloma used for cell fusion.
- cells having HGPRT or TK deficiency can be selected by culturing in a HAT culture solution (a culture solution containing hypoxanthine, aminopterin and thymidine). That is, when HAT-sensitive myeloma cells are used for cell fusion, cells that have succeeded in cell fusion with normal cells can be selectively proliferated in the HAT culture solution.
- the culture using the HAT culture solution is continued for a time sufficient for cells other than the target hybridoma (non-fusion cells) to die.
- the target hybridoma can be selected by culturing for several days to several weeks. Subsequently, by carrying out the usual limiting dilution method, screening and single cloning of the hybridoma producing the target antibody can be performed.
- an antibody recognizing LGR7 can be prepared by the method described in International Publication WO03 / 104453.
- Screening and single cloning of the target antibody can be suitably performed by a screening method based on a known antigen-antibody reaction.
- the antigen is bound to a carrier such as beads made of polystyrene or the like, or a commercially available 96-well microtiter plate, and reacted with the culture supernatant of the hybridoma.
- a secondary antibody labeled with an enzyme is reacted. If the culture supernatant contains an antibody of interest that reacts with the sensitizing antigen, the secondary antibody binds to the carrier via this antibody. By detecting the secondary antibody that finally binds to the carrier, it can be determined whether the antibody of interest is present in the culture supernatant.
- substantially the same LGR7 protein can be preferably used as the antigen, including those used for immunization.
- a cell line expressing LGR7, an extracellular domain of LGR7, or an oligopeptide consisting of a partial amino acid sequence constituting the region can be used as an antigen.
- a target antibody can be obtained by sensitizing human lymphocytes with an antigen.
- human lymphocytes are first sensitized with LGR7 protein in vitro.
- the immunized lymphocytes are then fused with an appropriate fusion partner.
- the fusion partner for example, a myeloma cell derived from human and having a permanent division ability can be used (see Japanese Patent Publication No. 1-59878).
- the anti-LGR7 antibody obtained by this method is a human antibody having binding activity to LGR7 protein.
- anti-LGR7 can be obtained by administering an LGR7 protein as an antigen to a transgenic animal having all repertoires of human antibody genes or by immunizing with DNA constructed to express LGR7 in the animal.
- Human antibodies can also be obtained.
- Antibody-producing cells of the immunized animal can be immortalized by treatment such as cell fusion with an appropriate fusion partner or Epstein-Barr virus infection. From the immortalized cells thus obtained, a human antibody against the LGR7 protein can be isolated (see International Publication WO 94/25585, WO 93/12227, WO 92/03918, WO 94/02602). Further, by cloning the immortalized cell, a cell producing an antibody having the desired reaction specificity can also be cloned.
- the hybridoma producing the monoclonal antibody thus produced can be subcultured in a normal culture solution.
- the hybridoma can also be stored for a long time in liquid nitrogen.
- the hybridoma can be cultured according to a usual method, and the target monoclonal antibody can be obtained from the culture supernatant.
- a hybridoma can be administered to a mammal compatible therewith to proliferate and a monoclonal antibody can be obtained as its ascites.
- the former method is suitable for obtaining a highly pure antibody.
- an antibody encoded by an antibody gene cloned from an antibody-producing cell can also be used.
- the cloned antibody gene can be expressed as an antibody by incorporating it into an appropriate vector and introducing it into a host. Methods for isolation of antibody genes, introduction into vectors, and transformation of host cells have already been established (eg, Vandamme, A. M. et al., Eur.J. Biochem. (1990)). 192, 767-775).
- cDNA encoding the variable region (V region) of an anti-LGR7 antibody can be obtained from a hybridoma cell that produces the anti-LGR7 antibody.
- total RNA is extracted from the hybridoma.
- the following method can be used. Guanidine ultracentrifugation (Chirgwin, J. M. et al., Biochemistry (1979) 18, 5294-5299) AGPC method (Chomczynski, P. et al., Anal. Biochem. (1987) 162, 156-159)
- Extracted mRNA can be purified using mRNA “Purification” Kit (manufactured by GE Healthcare Bioscience) or the like. Alternatively, kits for extracting total mRNA directly from cells, such as QuickPrep mRNA Purification Kit (manufactured by GE Healthcare Bioscience), are also commercially available. Using such a kit, total mRNA can also be obtained from the hybridoma. From the obtained mRNA, cDNA encoding the antibody V region can be synthesized using reverse transcriptase. Any 15-30 base sequence selected from sequences common to mouse antibody genes can be used as a primer. Specifically, cDNA encoding the antibody V region can be obtained by using a primer having the DNA sequence shown in SEQ ID NOs: 97 to 100.
- cDNA can be synthesized by AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (manufactured by Seikagaku Corporation).
- AMV Reverse Transcriptase First-strand cDNA Synthesis Kit manufactured by Seikagaku Corporation.
- 5'-Ampli FINDER RACE Kit (Clontech) and 5'-RACE method using PCR (Frohman, M. A. et al., Proc. Natl. Acad. Sci. USA (1988) 85, 8998-9002, Belyavsky, A. et al., Nucleic Acids Res. (1989) 17, 2919-2932).
- appropriate restriction enzyme sites described later can be introduced at both ends of the cDNA.
- the desired cDNA fragment is purified from the obtained PCR product and then ligated with vector DNA.
- a recombinant vector is produced, introduced into Escherichia coli or the like and a colony is selected, a desired recombinant vector can be prepared from Escherichia coli that has formed the colony. Then, the base sequence of the cDNA can be confirmed by a known method such as the dideoxynucleotide chain termination method.
- a cDNA library can be used to obtain a gene encoding the variable region of an antibody.
- cDNA is synthesized using mRNA extracted from antibody-producing cells as a template to obtain a cDNA library. It is convenient to use a commercially available kit for the synthesis of the cDNA library. Actually, the amount of mRNA obtained from only a small number of cells is extremely small, and the yield is low when it is directly purified. Therefore, it is usually purified after adding carrier RNA that is apparently free of antibody genes. Alternatively, when a certain amount of RNA can be extracted, it is possible to efficiently extract only RNA of antibody-producing cells. For example, carrier RNA may not be necessary for RNA extraction from 10 or more, 30 or more, preferably 50 or more antibody-producing cells.
- Antibody gene is amplified by PCR using the obtained cDNA library as a template.
- Primers for amplifying antibody genes by PCR are known.
- primers for human antibody gene amplification can be designed based on the disclosure of a paper (J. Mol. Biol. (1991) 222, 581-597). These primers have different nucleotide sequences for each immunoglobulin subclass. Therefore, when a cDNA library whose subclass is unknown is used as a template, the PCR method is performed in consideration of all possibilities.
- a primer capable of amplifying genes encoding ⁇ 1 to ⁇ 5 as a heavy chain and ⁇ chain and ⁇ chain as a light chain may be used. it can.
- a primer that anneals to a portion corresponding to the hinge region is generally used as the 3′-side primer.
- a primer corresponding to each subclass can be used as the 5′-side primer.
- PCR products using primers for gene amplification of heavy and light chain subclasses should be independent libraries.
- an immunoglobulin comprising a combination of a heavy chain and a light chain can be reconstructed.
- the target antibody can be screened using the binding activity of the reconstituted immunoglobulin to LGR7 as an index.
- the binding of the antibody to LGR7 is more preferably specific.
- Antibodies that bind to LGR7 can be screened, for example, as follows. (1) contacting an antibody comprising a V region encoded by the obtained cDNA with LGR7; (2) detecting the binding between LGR7 and the antibody, and (3) Step of selecting an antibody that binds to LGR7
- a method for detecting the binding between the antibody and LGR7 is known. Specifically, the test antibody is reacted with LGR7 immobilized on a carrier, and then a labeled antibody that recognizes the antibody is reacted. When the labeled antibody on the carrier is detected after washing, the binding of the test antibody to LGR7 can be proved.
- an enzyme active protein such as peroxidase or ⁇ -galactosidase, or a fluorescent substance such as FITC can be used.
- a fixed specimen of cells expressing LGR7 can also be used.
- a panning method using a phage vector can also be used.
- the antibody gene is obtained as a heavy chain and light chain subclass library as described above, a screening method using a phage vector is advantageous.
- a gene encoding the variable region of the heavy chain and the light chain can be converted into a single chain Fv (scFv) by linking with an appropriate linker sequence. If a gene encoding scFv is inserted into a phage vector, a phage expressing scFv on the surface can be obtained. By contacting the phage with the target antigen and recovering the phage bound to the antigen, the DNA encoding scFv having the target binding activity can be recovered. By repeating this operation as necessary, scFv having the desired binding activity can be concentrated.
- the polynucleotide encoding the antibody may encode the full length of the antibody or may encode a part of the antibody.
- a part of an antibody refers to any part of an antibody molecule.
- an antibody fragment may be used as a term indicating a part of an antibody.
- a preferred antibody fragment in the present invention contains a complementarity determination region (CDR) of an antibody. More preferably, the antibody fragment of the present invention includes all three CDRs constituting the variable region.
- the cDNA is digested with a restriction enzyme that recognizes restriction enzyme sites inserted at both ends of the cDNA.
- a preferred restriction enzyme recognizes and digests a base sequence that is unlikely to appear in the base sequence constituting the antibody gene.
- a restriction enzyme that provides a sticky end is preferred.
- An antibody expression vector can be obtained by inserting the cDNA encoding the V region of the anti-LGR7 antibody digested as described above into an appropriate expression vector.
- a chimeric antibody can be obtained by fusing the gene encoding the antibody constant region (C region) and the gene encoding the V region in-frame.
- the term “chimeric antibody” means that the origins of the constant region and the variable region are different. Accordingly, in addition to a heterologous chimeric antibody such as mouse-human, a human-human homologous chimeric antibody is also included in the chimeric antibody of the present invention. It is also possible to construct a chimeric antibody expression vector by inserting a V region gene into an expression vector in which a DNA encoding a constant region is previously incorporated.
- a restriction enzyme recognition sequence for a restriction enzyme that digests a V region gene is placed on the 5 ′ side of an expression vector holding DNA encoding a desired antibody constant region (C region).
- C region DNA encoding a desired antibody constant region
- a chimeric antibody expression vector is constructed by digesting both with the same combination of restriction enzymes and fusing them in frame.
- the antibody gene can be incorporated into an expression vector so as to be expressed under the control of the expression control region.
- An expression control region for expressing an antibody includes, for example, an enhancer and a promoter. Subsequently, by transforming an appropriate host cell with this expression vector, a recombinant cell expressing DNA encoding the anti-LGR7 antibody can be obtained.
- DNAs encoding antibody heavy chains (H chains) and light chains (L chains) can be incorporated into separate expression vectors.
- An antibody molecule having an H chain and an L chain can be expressed by co-transfecting a vector incorporating the H chain and the L chain into the same host cell at the same time.
- DNA encoding the H chain and L chain may be incorporated into a single expression vector to transform host cells (see International Publication WO94 / 11523).
- a host and an expression vector for producing an antibody by introducing an isolated antibody gene into a suitable host are known. Any of these expression systems can be applied to the present invention.
- animal cells, plant cells, or fungal cells can be used.
- the following cells can be exemplified as animal cells that can be used in the present invention.
- Mammalian cells CHO, COS, myeloma, BHK (baby hamster kidney), Hela, Vero, HEK293, Ba / F3, HL-60, Jurkat, SK-HEP1, etc.
- Amphibian cells Xenopus oocytes
- Insect cells sf9, sf21, Tn5, etc.
- an antibody gene expression system using cells from the genus Nicotiana such as Nicotiana tabacum is known.
- Callus cultured cells can be used for transformation of plant cells.
- Yeast genus Saccharomyces such as Saccharomyces serevisiae, genus Pichia such as Pichia pastoris such as Saccharomyces serevisiae: genus Aspergillus such as Aspergillus niger
- antibody gene expression systems using prokaryotic cells are also known.
- bacterial cells such as E. coli and Bacillus subtilis can be used in the present invention.
- the promoter / enhancer can include human cytomegalovirus early promoter / enhancer (human cytomegalovirus immediate-promoter / enhancer).
- a promoter / enhancer derived from a mammalian cell such as a viral promoter / enhancer or human elongation factor 1 ⁇ (HEF1 ⁇ ) can be used for antibody expression.
- viruses that can utilize promoters / enhancers include retroviruses, polyomaviruses, adenoviruses, and simian virus 40 (SV40).
- the method of Mulligan et al. (Nature (1979) 277, 108) can be used. Further, the HEF1 ⁇ promoter / enhancer can be easily used for target gene expression by the method of Mizushima et al. (Nucleic Acids Res. (1990) 18, 5322).
- the gene can be expressed by functionally combining a useful promoter commonly used, a signal sequence for antibody secretion, and an antibody gene to be expressed.
- the promoter include lacZ promoter and araB promoter.
- the lacZ promoter the method of Ward et al. (Nature (1989) 341, 544-546; FASEBJ. (1992) 6, 2422-2427) can be used.
- the araB promoter can be used for the expression of the target gene by the method of Better et al. (Science (1988) 240, 1041-1043).
- a pelB signal sequence (Lei, S. P. et al., J. Bacteriol. (1987) 169, 4379) may be used when the periplasm of E. coli is produced. Then, after separating the antibody produced in the periplasm, the structure of the antibody is refolded to have the desired binding activity by using a protein denaturant such as guanidine hydrochloride of urea.
- the signal sequence of the antibody heavy chain gene or light chain gene is desirable to use as the signal sequence required for secretion outside the cell. It is also possible to use signal sequences possessed by secreted proteins such as IL-3 and IL-6.
- a selectable marker can be inserted into the expression vector for amplification of the gene copy number in the host cell system. Specifically, the following selection markers can be used.
- Host cells are cultured according to a known method.
- DMEM, MEM, RPMI1640, and IMDM can be used as the culture medium, and serum supplements such as fetal calf serum (FCS) can be used in combination.
- FCS fetal calf serum
- the antibody expressed and produced as described above can be purified by using a known method used in normal protein purification alone or in combination as appropriate.
- antibodies can be separated and purified by appropriately selecting and combining affinity columns such as protein A columns, chromatography columns, filters, ultrafiltration, salting out, dialysis, etc. (Antibodies A Laboratory Manual. Ed Harlow , David David Lane, Cold Spring Spring Laboratory, 1988).
- transgenic animals can also be used for the production of recombinant antibodies. That is, the antibody can be obtained from an animal into which a gene encoding the target antibody has been introduced.
- an antibody gene can be constructed as a fusion gene by inserting in frame into a gene that encodes a protein that is uniquely produced in milk.
- a protein secreted into milk for example, goat ⁇ -casein can be used.
- the DNA fragment containing the fusion gene into which the antibody gene has been inserted is injected into a goat embryo, and the injected embryo is introduced into a female goat.
- the desired antibody can be obtained as a fusion protein with milk protein from milk produced by a transgenic goat (or its offspring) born from a goat that has received the embryo.
- hormones can be used as appropriate in transgenic goats to increase the amount of milk containing the desired antibody produced from the transgenic goat (Ebert, KM et al., Bio / Technology (1994) 12, 699-702). ).
- C region of the recombinant antibody of the present invention a C region derived from a non-human animal antibody can be used.
- C ⁇ 1, C ⁇ 2a, C ⁇ 2b, C ⁇ 3, C ⁇ , C ⁇ , C ⁇ 1, C ⁇ 2, C ⁇ can be used as the H chain C region of the mouse antibody
- C ⁇ , C ⁇ can be used as the L chain C region.
- antibodies such as rats, rabbits, goats, sheep, camels and monkeys can be used as antibodies from animals other than mice. These sequences are known.
- the C region can be modified to improve the stability of the antibody or its production.
- an antibody when administered to a human, it can be a genetically modified antibody that has been artificially modified for the purpose of reducing the heterologous antigenicity of the human.
- the recombinant antibody includes, for example, a chimeric antibody and a humanized antibody. These modified antibodies can be produced using known methods.
- Chimeric antibody refers to an antibody in which variable regions and constant regions derived from each other are linked.
- an antibody consisting of the variable regions of the heavy and light chains of a mouse antibody and the constant regions of the heavy and light chains of a human antibody is a mouse-human-heterologous chimeric antibody.
- a recombinant vector that expresses a chimeric antibody can be prepared by linking DNA encoding the variable region of a mouse antibody to DNA encoding the constant region of a human antibody and incorporating it into an expression vector.
- the chimeric antibody produced in the culture can be obtained by culturing recombinant cells transformed with the vector and expressing the incorporated DNA.
- a human antibody is used for the C region of the chimeric antibody and the humanized antibody.
- C ⁇ 1, C ⁇ 2, C ⁇ 3, C ⁇ 4, C ⁇ , C ⁇ , C ⁇ 1, C ⁇ 2, and C ⁇ can be used as the C region.
- C ⁇ and C ⁇ can be used as the C region.
- the amino acid sequences of these C regions, as well as the base sequences encoding them, are known.
- the human antibody C region can be modified to improve the stability of the antibody itself or the production of the antibody.
- a chimeric antibody is composed of a V region of an antibody derived from a non-human animal and a C region derived from a human antibody.
- humanized antibodies include complementarity determining regions (CDRs) of non-human animal-derived antibodies, framework regions derived from human antibodies (FR; framework regions), and C regions derived from human antibodies. Consists of Since humanized antibodies have reduced antigenicity in the human body, they are useful as the active ingredient of the therapeutic agent of the present invention.
- Antibody variable regions are usually composed of three complementarity-determining regions (CDRs) sandwiched between four frames (FR).
- CDRs are regions that substantially determine the binding specificity of an antibody.
- the amino acid sequence of CDR is rich in diversity.
- the amino acid sequence constituting FR often shows high homology among antibodies having different binding specificities. Therefore, it is generally said that the binding specificity of one antibody can be transplanted to another antibody by CDR grafting.
- Humanized antibodies are also referred to as reshaped human antibodies. Specifically, non-human animals, for example, humanized antibodies obtained by grafting mouse antibody CDRs to human antibodies are known. General genetic recombination techniques for obtaining humanized antibodies are also known.
- overlap extension PCR is known as a method for transplanting mouse antibody CDRs to human FRs.
- PCR extension the base sequence which codes CDR of the mouse antibody which should be transplanted is added to the primer for synthesize
- selection of human FRs having high homology with mouse FRs is advantageous in maintaining CDR function. That is, generally, it is preferable to use a human FR comprising an amino acid sequence having high homology with the amino acid sequence of the FR adjacent to the mouse CDR to be transplanted.
- the base sequences to be linked are designed to be connected to each other in frame.
- Human FRs are synthesized individually by each primer.
- a product in which DNA encoding mouse CDR is added to each FR is obtained.
- the base sequences encoding mouse CDRs of each product are designed to overlap each other.
- the overlapping CDR portions of the products synthesized using the human antibody gene as a template are annealed with each other to perform a complementary chain synthesis reaction. By this reaction, human FRs are linked via the mouse CDR sequence.
- a human-type antibody expression vector can be prepared by inserting the DNA obtained as described above and a DNA encoding the human antibody C region into an expression vector so as to be fused in frame. After introducing this vector into a host to establish recombinant cells, the recombinant cells are cultured, and the DNA encoding the humanized antibody is expressed, whereby the humanized antibody is produced in the culture of the cultured cells. (See European Patent Publication EP 239400, International Publication WO 96/02576).
- the CDR forms a favorable antigen-binding site when linked via CDR.
- a human antibody FR can be suitably selected.
- FR amino acid residues can be substituted so that the CDR of the reshaped human antibody forms an appropriate antigen-binding site.
- amino acid sequence mutations can be introduced into FRs by applying the PCR method used for transplantation of mouse CDRs into human FRs.
- partial nucleotide sequence mutations can be introduced into primers that anneal to the FR.
- a nucleotide sequence mutation is introduced into the FR synthesized by such a primer.
- a mutant FR sequence having a desired property can be selected by measuring and evaluating the antigen-binding activity of a mutant antibody substituted with an amino acid by the above method (Sato, K.et al., Cancer Res, 1993, 53 , 851-856).
- a method for obtaining a human antibody is also known.
- human lymphocytes are sensitized with the desired antigen or cells expressing the desired antigen in vitro.
- a desired human antibody having an antigen-binding activity can be obtained by fusing sensitized lymphocytes with human myeloma cells (see Japanese Patent Publication No. 1-59878).
- U266 can be used as a human myeloma cell as a fusion partner.
- a desired human antibody can be obtained by immunizing a transgenic animal having all repertoires of human antibody genes with a desired antigen (International Publication WO 93/12227, WO 92/03918, WO 94/02602, WO 94/25585, WO 96/34096, WO 96/33735).
- a technique for obtaining a human antibody by panning using a human antibody library is also known.
- the V region of a human antibody is expressed as a single chain antibody (scFv) on the surface of the phage by the phage display method, and a phage that binds to the antigen can be selected.
- the DNA sequence encoding the V region of the human antibody that binds to the antigen can be determined. After determining the DNA sequence of scFv that binds to the antigen, the V region sequence is fused in-frame with the sequence of the desired human antibody C region, and then inserted into an appropriate expression vector, whereby an expression vector can be prepared.
- the human antibody can be obtained by introducing the expression vector into a suitable expression cell as described above and expressing the gene encoding the human antibody. These methods are already known (International Publication WO 92/01047, WO 92/20791, WO 93/06213, WO 93/11236, WO 93/19172, WO 95/01438, WO 95/15388). Accordingly, one preferred embodiment of the antibody used in the present invention is an antibody having a human constant region.
- the antibody of the present invention includes not only a bivalent antibody represented by IgG but also a monovalent antibody or a multivalent antibody represented by IgM as long as it binds to the LGR7 protein.
- the multivalent antibodies of the present invention include multivalent antibodies that all have the same antigen-binding site, or multivalent antibodies that have some or all different antigen-binding sites.
- the antibody of the present invention is not limited to the full-length antibody molecule, and may be a low molecular weight antibody or a modified product thereof as long as it binds to LGR7 protein.
- the low molecular weight antibody includes an antibody fragment in which a part of a full-length antibody (whole antibody, such as whole IgG) is deleted. As long as it has the ability to bind to the LGR7 antigen, partial deletion of the antibody molecule is tolerated.
- the antibody fragment in the present invention preferably contains either or both of a heavy chain variable region (VH) and a light chain variable region (VL).
- VH heavy chain variable region
- VL light chain variable region
- the antibody fragment in the present invention preferably contains CDR.
- the amino acid sequence of VH or VL can include substitutions, deletions, additions and / or insertions.
- VH and VL can be deleted.
- the variable region may be chimerized or humanized.
- antibody fragments include, for example, Fab, Fab ′, F (ab ′) 2, and Fv.
- Specific examples of the low molecular weight antibody include, for example, Fab, Fab ′, F (ab ′) 2, Fv, scFv (single chain Fv), diabody, sc (Fv) 2 (single chain (Fv) 2 ), ScFv-Fc, and the like. Multimers of these antibodies (eg, dimer, trimer, tetramer, polymer) are also included in the low molecular weight antibody of the present invention.
- Antibody fragments can be obtained by treating antibodies with enzymes to generate antibody fragments.
- enzymes that produce antibody fragments include, for example, papain, pepsin, and plasmin.
- genes encoding these antibody fragments can be constructed, introduced into an expression vector, and then expressed in an appropriate host cell (for example, Co, MS et al., J. Immunol. (1994) 152). , 2968-2976, Better, M. & Horwitz, A. H. Methods in Enzymology (1989) 178, 476-496, Plueckthun, A. & Skerra, A.
- the digestive enzyme cleaves a specific position of the antibody fragment to give an antibody fragment having a specific structure as follows. If a genetic engineering technique is used for such an enzymatically obtained antibody fragment, any part of the antibody can be deleted. Papain digestion: F (ab) 2 or Fab Pepsin digestion: F (ab ') 2 or Fab' Plasmin digestion: Facb
- the low molecular weight antibody in the present invention can be an antibody fragment lacking any region as long as it has binding affinity for LGR7. Further, particularly in the treatment of cell proliferative diseases such as cancer according to the present invention, it is desirable that the antibody maintain its effector activity. That is, a preferred low molecular weight antibody in the present invention has both a binding affinity for LGR7 and an effector function.
- Antibody effector functions include ADCC activity and CDC activity.
- the therapeutic antibody in the present invention particularly preferably comprises one or both of ADCC activity and CDC activity as an effector function.
- Diabody refers to a bivalent antibody fragment constructed by gene fusion (Holliger Pet et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993), EP 404,097, WO93 / 11161 etc.).
- Diabodies are dimers composed of two polypeptide chains. Usually, in the polypeptide chain constituting the dimer, VL and VH are connected by a linker in the same chain. The linker in the diabody is generally so short that VL and VH cannot bind to each other. Specifically, the amino acid residues constituting the linker are, for example, about 5 residues. Therefore, VL and VH encoded on the same polypeptide chain cannot form a single chain variable region fragment but form a dimer with another single chain variable region fragment. As a result, the diabody has two antigen binding sites.
- ScFv can be obtained by linking antibody H chain V region and L chain V region.
- the H chain V region and the L chain V region are linked via a linker, preferably a peptide linker (Huston, J. S. et al., Proc. Natl. Acad. Sci. USA, 1988, 85). , 5879-5883.).
- the H chain V region and L chain V region in scFv may be derived from any of the antibodies described herein.
- region For example, any single chain peptide consisting of about 3 to 25 residues can be used as a linker. Specifically, for example, a peptide linker described later can be used.
- the V regions of both chains can be linked by, for example, the PCR method as described above.
- the DNA encoding the desired partial amino acid sequence is used as a template.
- the DNAs encoding the V region of the H chain and the L chain are each amplified by PCR using a pair of primers having sequences corresponding to the sequences at both ends of the DNA to be amplified.
- DNA encoding a peptide linker portion is prepared.
- DNA encoding a peptide linker can also be synthesized using PCR.
- a base sequence that can be linked to the amplification product of each V region synthesized separately is added to the 5 ′ side of the primer to be used.
- PCR reaction is performed using each DNA of [H chain V region DNA]-[peptide linker DNA]-[L chain V region DNA] and assembly PCR primers.
- the primer for assembly PCR consists of a combination of a primer that anneals to the 5 'side of [H chain V region DNA] and a primer that anneals to the 3' side of [L chain V region DNA]. That is, the assembly PCR primer is a primer set that can amplify DNA encoding the full-length sequence of scFv to be synthesized. On the other hand, a base sequence that can be linked to each V region DNA is added to [peptide linker DNA]. As a result, these DNAs are ligated, and the full length of scFv is finally produced as an amplification product by the primers for assembly PCR.
- an expression vector containing them and a recombinant cell transformed with the expression vector can be obtained according to a conventional method. Further, the scFv can be obtained by culturing the resulting recombinant cells and expressing the DNA encoding the scFv.
- scFv-Fc is a low molecular weight antibody in which an Fc region is fused to an scFv composed of an H chain V region and an L chain V region of an antibody (Cellular & Molecular Immunology 2006; 3: 439-443).
- the origin of scFv used for scFv-Fc is not specifically limited, For example, scFv derived from IgM can be used.
- the origin of Fc is not particularly limited, and for example, mouse IgG (such as mouse IgG2a) and human IgG (such as human IgG1) can be used.
- scFv-Fc scFv- fragment obtained by linking the scFv fragment of IgM antibody and mouse IgG2a CH2 (eg, C ⁇ 2) and CH3 (eg, C ⁇ 3) with mouse IgG2a hinge region (H ⁇ ).
- Examples include Fc, scFv fragment of IgM antibody, and scFv-Fc in which CH2 and CH3 of human IgG1 are linked by the hinge region of human IgG1.
- sc (Fv) 2 is a low molecular weight antibody in which two VHs and two VLs are combined with a linker or the like to form a single chain (Hudson et al, J Immunol. Methods 1999; 231: 177-189).
- sc (Fv) 2 can be prepared, for example, by linking scFv with a linker.
- Two VHs and two VLs are arranged in the order of VH, VL, VH, and VL ([VH] linker [VL] linker [VH] linker [VL]) starting from the N-terminal side of the single-chain polypeptide.
- the order of the two VHs and the two VLs is not particularly limited to the above arrangement, and may be arranged in any order. For example, the following arrangements can also be mentioned.
- a peptide linker is preferred.
- the length of the peptide linker is not particularly limited, and can be appropriately selected by those skilled in the art according to the purpose.
- the amino acid residues constituting the peptide linker are 1 to 100 amino acids, preferably 3 to 50 amino acids, more preferably 5 to 30 amino acids, particularly preferably 12 to 18 amino acids (for example, 15 amino acids).
- the amino acid sequence constituting the peptide linker can be any sequence as long as it does not inhibit the scFv binding action.
- the following amino acid sequence can be used.
- n which determines the length of the above peptide linker is usually 1 to 5, preferably 1 to 3, more preferably 1 or 2.
- sc (Fv) 2 examples include the following sc (Fv) 2.
- V regions can be linked using a synthetic chemical linker (chemical cross-linking agent).
- a crosslinking agent usually used for crosslinking such as peptide compounds can be used in the present invention.
- the following chemical crosslinking agents are known. These crosslinking agents are commercially available.
- N-hydroxysuccinimide (NHS), Disuccinimidyl suberate (DSS), Bis (sulfosuccinimidyl) suberate (BS3), Dithiobis (succinimidyl propionate) (DSP), Dithiobis (sulfosuccinimidyl propionate) (DTSSP), Ethylene glycol bis (succinimidyl succinate) (EGS), Ethylene glycol bis (sulfosuccinimidyl succinate) (sulfo-EGS), Disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), Bis [2- (succinimideoxycarbonyloxy) ethyl] sulfone (BSOCOES), bis [2- (sulfosuccinimideoxycarbonyloxy) ethyl] sulfone (sulfo-BSOCOES), etc
- the preferred low molecular weight antibody in the present invention is diabody or sc (Fv) 2.
- the antibody is treated with an enzyme such as papain or pepsin to generate antibody fragments, or DNA encoding these antibody fragments is constructed and used as an expression vector.
- expression in an appropriate host cell for example, Co, M. S. et al., J. Immunol. (1994) 152, 2968-2976; Better, M. and Horwitz, A. H Methods Enzymol. (1989) 178, 476-496; Pluckthun, A.
- the antibody of the present invention includes not only a monovalent antibody but also a multivalent antibody.
- the multivalent antibodies of the present invention include multivalent antibodies that all have the same antigen-binding site, or multivalent antibodies that have some or all different antigen-binding sites.
- An antibody conjugated with various molecules such as polyethylene glycol (PEG) can also be used as a modified antibody. It is also possible to bind a cytotoxic substance such as a chemotherapeutic agent, a toxic peptide or a radioactive chemical substance to the antibody.
- a modified antibody hereinafter referred to as antibody conjugate
- Such a modified antibody can be obtained by chemically modifying the obtained antibody.
- the modification method of an antibody has already been established in this field.
- bispecific antibodies bispecific antibodies (bispecific antibodies) designed using genetic recombination technology to recognize not only LGR7 protein but also cytotoxic substances such as chemotherapeutic agents, toxic peptides and radioactive chemicals ) As a molecular type. These antibodies are also included in the “antibody” in the present invention.
- a preferable chemotherapeutic agent is a low-molecular chemotherapeutic agent.
- Small molecule chemotherapeutic agents are less likely to interfere with antibody function after binding to the antibody.
- the low-molecular chemotherapeutic agent usually has a molecular weight of 100 to 2000, preferably 200 to 1000.
- the chemotherapeutic agents exemplified here are all low-molecular chemotherapeutic agents.
- These chemotherapeutic agents in the present invention include a prodrug that is converted into an active chemotherapeutic agent in vivo. Activation of the prodrug may be enzymatic conversion or non-enzymatic conversion.
- the antibody can also be modified with a toxic peptide.
- a toxic peptide the following can be mentioned, for example. Diphtheria toxin A chain (Diphtheria toxin A Chain) (Langone JJ, et al., Methods in Enzymology, 93,307-308,1983), Pseudomonas ⁇ ⁇ ⁇ Exotoxin (Nature Medicine, 2,350-353,1996), lysine chain (Ricin) A Chain) (Fulton RJ, et al., J. Biol.
- the radioactive chemical substance refers to a chemical substance containing a radioisotope.
- the radioactive isotope is not particularly limited, and any radioactive isotope may be used.
- 32 P, 14 C, 125 I, 3 H, 131 I, 186 Re, 188 Re, etc. can be used. .
- one or two or more small molecule chemotherapeutic agents and toxic peptides can be used in combination to modify the antibody.
- Coupling between the anti-LGR7 antibody and the above small molecule chemotherapeutic agent can be covalent or non-covalent. Methods for producing antibodies bound with these chemotherapeutic agents are known.
- proteinaceous drugs and toxins can be bound to antibodies by genetic engineering techniques.
- a recombinant vector in which a DNA encoding the toxic peptide and a DNA encoding an anti-LGR7 antibody are fused in frame and incorporated into an expression vector can be constructed.
- a transformed cell obtained by introducing the vector into an appropriate host cell is cultured, and the incorporated DNA is expressed, whereby an anti-LGR7 antibody to which a toxic peptide is bound can be obtained as a fusion protein.
- a proteinaceous drug or toxin is generally arranged on the C-terminal side of the antibody.
- a peptide linker can be interposed between the antibody and the proteinaceous drug or toxin.
- the antibody of the present invention may be a bispecific antibody.
- Bispecific antibodies refer to antibodies that have variable regions that recognize different epitopes within the same antibody molecule.
- bispecific antibodies can have antigen binding sites that recognize different epitopes on the LGR7 molecule.
- Such a bispecific antibody can bind two antibody molecules to one molecule of LGR7. As a result, a stronger cytotoxic effect can be expected.
- a bispecific antibody in which one antigen-binding site recognizes LGR7 and the other antigen-binding site recognizes a cytotoxic substance can also be used.
- the cytotoxic substance includes a chemotherapeutic agent, a toxic peptide, a radioactive chemical substance, and the like.
- Such bispecific antibodies capture cytotoxic substances while binding to cells expressing LGR7. As a result, the cytotoxic substance can directly act on LGR7-expressing cells. That is, the bispecific antibody that recognizes the cytotoxic substance can specifically damage the tumor cell and suppress the growth of the tumor cell.
- bispecific antibodies that recognize antigens other than LGR7 can also be combined.
- a bispecific antibody that recognizes an antigen that is specifically expressed on the cell surface of the target cancer cell and is different from LGR7 can be combined.
- bispecific antibodies can be produced by combining two types of antibodies with different recognition antigens.
- the antibody to be bound may be a 1 ⁇ 2 molecule each having an H chain and an L chain, or may be a 1 ⁇ 4 molecule consisting only of an H chain.
- bispecific antibody-producing fused cells can be prepared by fusing hybridomas that produce different monoclonal antibodies.
- bispecific antibodies can be produced by genetic engineering techniques.
- ELISA enzyme-linked immunosorbent assay
- EIA enzyme immunoassay
- RIA radioimmunoassay
- fluorescent immunoassay can be used.
- the antibody of the present invention may be an antibody having a modified sugar chain. It is known that the cytotoxic activity of an antibody can be enhanced by modifying the sugar chain of the antibody.
- an antibody with a modified sugar chain for example, the following antibody is known; Antibodies with modified glycosylation (eg WO99 / 54342), Antibodies lacking fucose added to the sugar chain (WO00 / 61739, WO02 / 31140, WO2006 / 067913, etc.) An antibody (such as WO02 / 79255) having a sugar chain having bisecting GlcNAc.
- the antibody of the present invention is preferably an antibody having cytotoxic activity.
- the cytotoxic activity in the present invention include antibody-dependent cell-mediated cytotoxicity (ADCC) activity and complement-dependent cytotoxicity (CDC) activity.
- ADCC activity means cytotoxic activity by the complement system.
- ADCC activity means that when a specific antibody is attached to the cell surface antigen of the target cell, Fc ⁇ receptor-bearing cells (immune cells, etc.) bind to the Fc portion via the Fc ⁇ receptor, causing damage to the target cell. Means activity.
- Whether or not the anti-LGR7 antibody has ADCC activity or CDC activity can be measured by a known method (for example, Current protocols in Immunology, Chapter7. Immunologic studies in Humans, Editor, John E, Coligan et al., John Wiley & Sons, Inc., (1993)).
- effector cells Specifically, first, effector cells, complement solution, and target cells are prepared.
- (1) Preparation of effector cells Spleens are removed from CBA / N mice and the like, and spleen cells are isolated in RPMI1640 medium (Invitrogen). After washing with the same medium containing 10% fetal calf serum (FBS, HyClone), effector cells can be prepared by adjusting the cell concentration to 5 ⁇ 10 6 / ml.
- FBS fetal calf serum
- effector cells can be prepared by adjusting the cell concentration to 5 ⁇ 10 6 / ml.
- (2) Preparation of complement solution Baby Rabbit Complement (manufactured by CEDARLANE) is diluted 10-fold in a medium containing 10% FBS (manufactured by Invitrogen) to prepare a complement solution.
- target cells Culture cells expressing LGR7 protein with 0.2 mCi of 51Cr-sodium chromate (GE Healthcare Bioscience) in DMEM medium containing 10% FBS at 37 ° C for 1 hour.
- the target cell can be radiolabeled.
- cells that express LGR7 protein cells transformed with a gene encoding LGR7 protein, ovarian cancer, and the like can be used.
- the target cells can be prepared by washing the cells three times with 10% FBS-containing RPMI1640 medium and adjusting the cell concentration to 2 ⁇ 10 5 / ml.
- ADCC activity or CDC activity can be measured by the method described below.
- 50 ⁇ l each of target cells and anti-LGR7 antibody are added to a 96-well U-bottom plate (Becton ⁇ Dickinson) and allowed to react on ice for 15 minutes. Thereafter, 100 ⁇ l of effector cells are added and cultured for 4 hours in a carbon dioxide incubator. The final antibody concentration is 0 or 10 ⁇ g / ml. After incubation, 100 ⁇ l of the supernatant is collected, and the radioactivity is measured with a gamma counter (COBRAIIAAUTO-GAMMA, MODEL D5005, Packard Instruments Company).
- COBRAIIAAUTO-GAMMA MODEL D5005, Packard Instruments Company
- Cytotoxic activity (%) can be calculated based on the formula of (A-C) / (B-C) ⁇ 100 using the obtained value.
- A is the radioactivity (cpm) in each sample
- B is the radioactivity (cpm) in the sample with 1% NP-40 (manufactured by nacalai tesque)
- C is the radioactivity (cpm) of the sample containing only the target cells Show.
- an antibody having an internalizing activity means an antibody that is transported into a cell (intracytoplasm, in a vesicle, in another organelle, etc.) when bound to LGR7 on the cell surface.
- an anti-LGR7 antibody bound with a labeling substance is brought into contact with a cell expressing LGR7 and the labeling substance
- a method for confirming whether or not it has been taken into the cell a method for confirming whether cell death is induced in the LGR7-expressing cell by contacting an anti-LGR7 antibody conjugated with a cytotoxic substance with a cell expressing LGR7, etc. Can be confirmed. More specifically, it is possible to confirm whether or not an antibody has an internalizing activity by the method described in the Examples below.
- An antibody having an internalizing activity can be used as a pharmaceutical composition such as an anticancer agent by binding the above-described cytotoxic substance.
- any antibody that recognizes LGR7 can be used as the antibody of the present invention.
- the following antibodies (1) to (29) can be exemplified as preferred antibodies. These antibodies may be, for example, full length antibodies, low molecular weight antibodies, animal antibodies, chimeric antibodies, humanized antibodies, or human antibodies.
- having the same activity as the antibody of the present invention means that the binding activity to LGR7 and / or the cytotoxic activity to cells expressing LGR7 is equivalent.
- a method for introducing a mutation into a polypeptide is one of methods well known to those skilled in the art for preparing a polypeptide functionally equivalent to a certain polypeptide.
- those skilled in the art will recognize site-directed mutagenesis (Hashimoto-Gotoh, T. et al. (1995) Gene 152, 271-275, Zoller, MJ, and Smith, M. (1983) Methods Enzymol. 100 , 468-500, Kramer, W. et al. (1984) Nucleic Acids Res. 12, 9441-9456, Kramer W, and Fritz HJ (1987) Methods. Enzymol. 154, 350-367, Kunkel, TA (1985) Proc Natl Acad Sci USA.
- Antibodies can be prepared. Amino acid mutations can also occur in nature. Thus, an antibody having an amino acid sequence in which one or more amino acids are mutated in the amino acid sequence of the antibody of the present invention and functionally equivalent to the antibody is also included in the antibody of the present invention. In such mutants, the number of amino acids to be mutated is usually within 50 amino acids, preferably within 30 amino acids, and more preferably within 10 amino acids (for example, within 5 amino acids).
- the amino acid residue to be mutated is preferably mutated to another amino acid in which the properties of the amino acid side chain are conserved.
- the following classification has been established based on the properties of amino acid side chains.
- Hydrophobic amino acids (A, I, L, M, F, P, W, Y, V)
- Hydrophilic amino acids (R, D, N, C, E, Q, G, H, K, S, T)
- Amino acids with aliphatic side chains G, A, V, L, I, P
- An amino acid having a hydroxyl group-containing side chain S, T, Y
- Amino acids having side chains containing sulfur atoms C, M
- Amino acids with carboxylic acid and amide-containing side chains (D, N, E, Q)
- Amino acids with base-containing side chains (R, K, H)
- Amino acids with aromatic-containing side chains (H, F, Y, W) (In parentheses all represent one letter of amino acid)
- amino acid sequence classified into each group in an amino acid sequence constituting a certain polypeptide is highly likely to maintain the activity of the polypeptide when substituted with each other.
- substitution between amino acids in the group of amino acids is referred to as conservative substitution.
- the present invention also provides an antibody that binds to the same epitope as that to which the anti-LGR7 antibody disclosed in the present invention binds. That is, the present invention relates to an antibody that recognizes the same epitope recognized by 22DA6, 22DA7, 22DA17, 22DA22, 22DA23, 22DA24, 22SD7, 22SD11, and 22SD48, and uses thereof. Such an antibody can be obtained, for example, by the following method.
- test antibody shares an epitope with a certain antibody by competition for the same epitope.
- Competition between antibodies is detected by a cross-blocking assay or the like.
- a competitive ELISA assay is a preferred cross-blocking assay.
- the anti-LGR7 antibody of the present invention is added after pre-incubating the LGR7 protein coated on the well of the microtiter plate in the presence or absence of the candidate competitive antibody. Is done.
- the amount of the anti-LGR7 antibody of the present invention bound to the LGR7 protein in the well is indirectly correlated with the binding ability of the candidate competitive antibody (test antibody) that competes for binding to the same epitope. That is, the greater the affinity of the test antibody for the same epitope, the lower the binding amount of the anti-LGR7 antibody of the present invention to the well coated with the LGR7 protein, while the test antibody bound to the well coated with the LGR7 protein. The amount of binding increases.
- the amount of antibody bound to the well can be easily measured by labeling the antibody in advance.
- biotin-labeled antibodies can be measured by using an avidin peroxidase conjugate and an appropriate substrate.
- a cross-blocking assay using an enzyme label such as peroxidase is particularly referred to as a competitive ELISA assay.
- the antibody can be labeled with another labeling substance that can be detected or measured. Specifically, radiolabels or fluorescent labels are known.
- a competitive FACS assay is also a preferred cross-blocking assay.
- cells expressing LGR7 protein are used in place of LGR7 protein coated on the wells of a microtiter plate in a competitive ELISA assay.
- the competition between antibodies can be measured by adding the anti-LGR7 antibody of the present invention labeled with biotin after preincubation in the presence or absence of a candidate competing antibody and using a streptavidin fluorescein conjugate.
- a cross-blocking assay using flow cytometry is particularly referred to as a competitive FACS assay.
- the antibody can be labeled with another fluorescent labeling substance that can be detected or measured.
- any antibody bound to the well can be measured by a labeled antibody that recognizes any constant region.
- the antibodies bound to the wells can be measured by the antibodies that identify the respective classes.
- Anti-LGR7 antibody binding is at least 20%, preferably at least 30%, more preferably at least 50%, compared to the binding activity obtained in a control test performed in the absence of the candidate competing antibody Can block substantially the same epitope as the anti-LGR7 antibody of the invention, or is an antibody that competes for binding to the same epitope.
- the constant region of the antibody of the present invention may be replaced with the same constant region as that of the test antibody.
- the present invention provides a pharmaceutical composition containing an antibody that binds to LGR7 protein as an active ingredient.
- the present invention also relates to a cell growth inhibitor, particularly an anticancer agent, containing an antibody that binds to LGR7 protein as an active ingredient.
- the cytostatic agent and anticancer agent of the present invention are preferably administered to a subject suffering from or possibly suffering from cancer.
- the expression level of LGR7 is very low in normal cells other than the brain, but is increased in cancer cells. Therefore, it is considered that cytotoxicity specific to cancer cells can be obtained by administration of anti-LGR7 antibody.
- the anti-LGR7 antibody used in the pharmaceutical composition (for example, anticancer agent) of the present invention is not particularly limited, and may be any anti-LGR7 antibody.
- the above-described anti-LGR7 antibody can be used.
- “containing an antibody that binds to LGR7 as an active ingredient” means that the anti-LGR7 antibody is contained as a main active ingredient, and does not limit the content of the anti-LGR7 antibody.
- the target cancer is not particularly limited, but ovarian cancer is preferable, and ovarian cancer clear cell adenocarcinoma is particularly preferable.
- the cancer may be either a primary lesion or a metastatic lesion.
- the pharmaceutical composition of the present invention can be administered to a patient by either oral or parenteral administration. Preferably, it is parenteral administration. Specific examples of such administration methods include injection administration, nasal administration, transpulmonary administration, and transdermal administration.
- injection administration the pharmaceutical composition of the present invention can be administered systemically or locally by, for example, intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection and the like.
- the administration method can be appropriately selected depending on the age and symptoms of the patient.
- the dose for example, the dose can be selected in the range of 0.0001 mg to 1000 mg per kg of body weight per administration. Alternatively, for example, the dose can be selected in the range of 0.001 to 100,000 mg / body per patient.
- the pharmaceutical composition of the present invention is not limited to these doses.
- the pharmaceutical composition of the present invention can be formulated in accordance with a conventional method (for example, Remington's Pharmaceutical, Science, Latest Edition, Mark Publishing, Company, Easton, USA) together with pharmaceutically acceptable carriers and additives. It may be.
- a conventional method for example, Remington's Pharmaceutical, Science, Latest Edition, Mark Publishing, Company, Easton, USA
- pharmaceutically acceptable carriers and additives may be.
- it is not limited to these, and other commonly used carriers can be used as appropriate.
- silicic acid lactose, crystalline cellulose, mannitol, starch, carmellose calcium, carmellose sodium, hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylacetal diethylaminoacetate, polyvinylpyrrolidone, gelatin, medium chain fatty acid triglyceride
- the carrier include polyoxyethylene hydrogenated castor oil 60, sucrose, carboxymethylcellulose, corn starch, and inorganic salts.
- the present invention also provides a method of causing injury to LGR7-expressing cells or a method of suppressing cell proliferation by contacting LGR7-expressing cells with an antibody that binds to LGR7 protein.
- the antibody used in the method of the present invention is not particularly limited, and for example, the above-described antibodies can be used.
- the cell to which the anti-LGR7 antibody binds is not particularly limited as long as LGR7 is expressed.
- Preferred LGR7-expressing cells in the present invention are cancer cells. More preferred are ovarian cancer cells.
- the method of the present invention can be applied to both primary lesions and metastatic lesions of these cancers. Further preferred cancer cells are primary ovarian cancer cells and metastatic ovarian cancer cells.
- contact is performed, for example, by adding an antibody to a culture solution of LGR7-expressing cells cultured in a test tube.
- contact is also performed by administering to a non-human animal transplanted with LGR7-expressing cells into the body or an animal having cancer cells that endogenously express LGR7.
- the following method is preferably used as a method for evaluating or measuring the cytotoxicity caused to the LGR7-expressing cells by contact with the anti-LGR7 antibody.
- Methods for evaluating or measuring the cytotoxic activity in vitro include the above-described antibody-dependent cell-mediated cytotoxicity (ADCC) activity, complement-dependent cytotoxicity (complement-dependent cytotoxicity) : CDC) activity and the like. Whether an anti-LGR7 antibody has ADCC activity or CDC activity can be measured by a known method (for example, Current protocols in Immunology, Chapter 7. Immunologic studies in Humans, Editor, John E Coligan et al., John Wiley & Sons, Inc., (1993)).
- a binding antibody having the same isotype as the anti-LGR7 antibody and having no cytotoxic activity is used as a control antibody in the same manner as the anti-LGR7 antibody, and the anti-LGR7 antibody is stronger than the control antibody.
- Activity can be determined by showing cytotoxic activity.
- Antibody isotype is defined by the sequence of the H chain constant region of the amino acid sequence of the antibody. In vivo, the antibody isotype is finally determined by class switching caused by genetic recombination on the chromosome that occurs during maturation of antibody-producing B cells. Differences in isotypes are reflected in differences in the physiological and pathological functions of antibodies. Specifically, for example, it is known that the intensity of cytotoxic activity is influenced by the antibody isotype as well as the antigen expression level. Therefore, in the measurement of the cytotoxic activity described above, it is preferable to use the same isotype as the test antibody as the antibody used as a control.
- the test antibody is administered daily or at intervals of several days from that day or the next day Administer intravenously or intraperitoneally. Cytotoxic activity can be determined by measuring tumor size over time. Similar to the in vitro evaluation, a control antibody having the same isotype was administered, and the tumor size in the anti-LGR7 antibody administration group was significantly smaller than the tumor size in the control antibody administration group. Then it can be determined.
- a nude (nu / nu) mouse in which the thymus is genetically deleted and the function of the T lymphocyte is deleted can be preferably used.
- the mouse it is possible to eliminate the involvement of T lymphocytes in the test animal in the evaluation and measurement of the cytotoxic activity by the administered antibody.
- the present invention also provides a cancer diagnosis method characterized by detecting LGR7 protein or a gene encoding LGR7 protein.
- LGR7 is markedly enhanced in various cancer tissues or cancer cell lines, whereas LGR7 expression in normal cells is very low. Therefore, LGR7 is useful as a marker for specifically detecting cancer.
- cancer is diagnosed by detecting LGR7 protein in a sample.
- the extracellular region of LGR7 protein is detected.
- the detection of LGR7 protein is preferably performed using an antibody that recognizes LGR7 protein.
- One specific example of the diagnostic method of the present invention is a cancer diagnostic method including the following steps. (A) providing a sample collected from the subject; (B) A step of detecting the LGR7 protein contained in the collected sample using an antibody that binds to the LGR7 protein.
- detection includes quantitative or qualitative detection.
- qualitative detection can include the following measurements. Simply determine if LGR7 protein is present Measuring whether LGR7 protein is present in a certain amount or more Measurements comparing the amount of LGR7 protein with other samples (for example, control samples, etc.)
- quantitative detection can include measurement of the concentration of LGR7 protein, measurement of the amount of LGR7 protein, and the like.
- the test sample in the present invention is not particularly limited as long as it is a sample that may contain LGR7 protein.
- a sample collected from the body of a living organism such as a mammal is preferable. Further preferred samples are samples taken from humans.
- Specific examples of the test sample include, for example, blood, interstitial fluid, plasma, extravascular fluid, cerebrospinal fluid, synovial fluid, pleural fluid, serum, lymph fluid, saliva, urine, tissue, ascites, intraperitoneal washing fluid Etc. can be exemplified.
- a preferred sample is a sample obtained from a test sample such as a specimen in which tissues or cells collected from the body of an organism are fixed, or a culture solution of cells.
- the cancer diagnosed by the present invention is not particularly limited and may be any cancer. Specific examples include ovarian cancer. In the present invention, both primary lesions and metastatic lesions of these cancers can be diagnosed. Particularly preferred cancers in the present invention are primary ovarian cancer and metastatic ovarian cancer.
- the present invention when LGR7 protein is detected in a test sample, cancer is diagnosed using the level as an index. Specifically, when the amount of LGR7 protein detected in a test sample is higher than that in a negative control or healthy subject, the subject is more likely to have cancer or suffer from cancer in the future. Is shown. That is, the present invention relates to a method for diagnosing cancer including the following steps. (1) a step of detecting an LGR7 expression level in a biological sample collected from a subject, and (2) A step in which the subject is shown to have cancer when the expression level of LGR7 detected in (1) is higher than that of the control.
- the control refers to a sample as a reference for comparison, and includes a negative control and a biological sample of a healthy person.
- the negative control can be obtained by collecting a biological sample of a healthy person and mixing as necessary.
- the control expression level of LGR7 can be detected in parallel with the expression level of LGR7 in the biological sample of the subject.
- the expression level of LGR7 in biological samples of a large number of healthy subjects can be detected in advance, and the standard expression level in healthy subjects can be statistically determined. Specifically, for example, an average value ⁇ 2 ⁇ standard deviation (S.D.) or an average value ⁇ 3 ⁇ standard deviation (S.D.) can be used as the standard value.
- the mean ⁇ 2 ⁇ standard deviation (S.D.) contains 80% and the mean ⁇ 3 ⁇ standard deviation (S.D.) contains 90% of healthy subjects.
- the expression level of LGR7 in the control can be set using the ROC curve.
- An ROC curve (receiver operating characteristic curve; receiver operating characteristic curve) is a graph in which the vertical axis indicates detection sensitivity and the horizontal axis indicates a false positive rate (ie, “1-specificity”).
- an ROC curve can be obtained by plotting changes in sensitivity and false positive rate when the reference value for determining the expression level of LGR7 in a biological sample is continuously changed.
- the “reference value” for obtaining the ROC curve is a numerical value temporarily used for statistical analysis.
- the “reference value” for obtaining the ROC curve is generally changed continuously within a range that can cover all selectable reference values. For example, the reference value can be changed between the minimum value and the maximum value of LGR7 measurements of the population to be analyzed.
- a standard value statistically set by an ROC curve or the like is also called a cut-off value.
- the expression level of LGR7 detected in (1) is compared with the cutoff value in the step (2). Then, when the expression level of LGR7 detected in (1) is higher than the cut-off value, the subject's cancer is detected.
- the expression level of LGR7 can be determined by any method. Specifically, the expression level of LGR7 can be determined by evaluating the amount of LGR7 mRNA, the amount of LGR7 protein, and the biological activity of LGR7 protein. The amount of LGR7 mRNA or protein can be determined by the method described herein.
- any animal species that expresses the LGR7 protein can be the subject.
- chimpanzee Pan troglodytes
- ENSPTRG00000016551 rhesus monkey
- Macaca mulatta ENSMMUG00000004647
- mouse Mus musculus
- ENSMUSG00000034009 mouse
- rat Ratus norvegicus
- ENSCPOG000000155 guinea pig
- ENSCPOG000000155 It is known that many mammals other than humans such as familiaris) (ENSCAFG00000008672) and chicken (Gallus gallus) (ENSGALG00000009429) express LGR7 protein. Therefore, these animals are included in the subject in the present invention.
- a particularly suitable subject is a human. Needless to say, when the subject is an animal other than a human, the LGR7 protein of the animal species is detected.
- LGR7 protein contained in a test sample is not particularly limited, it is preferably detected by an immunological method as exemplified below using an anti-LGR7 antibody; Radioimmunoassay (RIA), Enzyme immunoassay (EIA), Fluorescence immunoassay (FIA), Luminescent immunoassay (LIA), Immunoprecipitation (IP), Immunoturbidimetry (TIA), Western blot (WB), Immunohistochemistry (IHC) method, Immune diffusion (SRID).
- RIA Radioimmunoassay
- EIA Enzyme immunoassay
- FIA Fluorescence immunoassay
- LIA Luminescent immunoassay
- IP Immunoprecipitation
- TAA Immunoturbidimetry
- WB Western blot
- IHC Immunohistochemistry
- the immunohistochemistry (IHC) method includes a step of detecting LGR7 protein on a section on which tissue or cells obtained from a patient suffering from cancer is immobilized, and is preferable as a method for diagnosing cancer.
- One of the immunological assay methods are methods known to those skilled in the art. That is, since LGR7 is a membrane protein whose expression is specifically enhanced in cancer cells, cancer cells or cancer tissues can be detected with an anti-LGR7 antibody.
- immunohistological analysis cancer cells contained in cells or tissues collected from a living body are detected.
- cancer tissue in a living body can be detected with an anti-LGR7 antibody.
- the present invention includes (1) administering to a subject an antibody that binds to an LGR7 protein labeled with a labeling substance such as a radioisotope, and (2) detecting the accumulation of the labeling substance. It relates to the detection method.
- the antibodies can be detectably labeled. For example, the behavior of a fluorescent substance, a luminescent substance, or an antibody labeled with a radioisotope in a living body can be traced. An antibody labeled with a fluorescent substance or a luminescent substance can be observed using an endoscope or a laparoscope.
- a radioisotope can image the localization of an antibody by following its radioactivity.
- the localization of the anti-LGR7 antibody in the living body indicates the presence of cancer cells.
- a positron emitting nuclide can be used as a radioisotope for labeling an antibody in order to detect cancer in vivo.
- the antibody can be labeled with positron emitting nuclides such as 18 F, 55 Co, 64 Cu, 66 Ga, 68 Ga, 76 Br, 89 Zr, and 124 I.
- a known method (Acta Oncol. 32, 825-830, 1993) can be used for labeling the anti-LGR7 antibody with these positron emitting nuclides.
- the radiation emitted by the radionuclide is measured from outside the body by PET (positron tomography) and converted to an image by computer tomography Is done.
- PET is a device for non-invasively obtaining data on the behavior of a drug in the body. With PET, radiation intensity can be quantitatively imaged as signal intensity.
- antigen molecules highly expressed in a specific cancer can be detected without collecting a sample from a patient.
- the anti-LGR7 antibody can be radiolabeled with a short-lived nuclide using a positron emitting nuclide such as 11 C, 13 N, 15 O, 18 F, and 45 Ti in addition to the above-mentioned nuclide.
- a positron emitting nuclide such as 11 C, 13 N, 15 O, 18 F, and 45 Ti in addition to the above-mentioned nuclide.
- an activity value of 25-4000 keV gamma particles or positron emission can be used appropriately.
- an appropriate nuclide is selected and administered in a larger amount, a therapeutic effect can be expected.
- a gamma particle of 70-700 keV or a nuclide that gives a positron emission value can be used.
- the expression of LGR7 gene is detected.
- the gene detected in the present invention is not particularly limited, but mRNA is preferable.
- detection includes quantitative or qualitative detection.
- the following measurement operation can be given as qualitative detection. Simply measuring whether LGR7 mRNA is present, Measurement of whether LGR7 mRNA is present above a certain amount, Measurements comparing the amount of LGR7 mRNA with other samples (eg, control samples)
- quantitative detection includes measurement of LGR7 mRNA concentration, measurement of LGR7 mRNA amount, etc. it can.
- test sample in the present invention any sample that may contain LGR7 mRNA can be used.
- a sample collected from the body of a living organism such as a mammal is preferable, and a sample collected from a human is more preferable.
- Specific examples of the test sample include, for example, blood, interstitial fluid, plasma, extravascular fluid, cerebrospinal fluid, synovial fluid, pleural fluid, serum, lymph fluid, saliva, urine, tissue, ascites, intraperitoneal washing fluid Etc. can be exemplified.
- a preferable sample includes a sample obtained from a test sample, such as a specimen in which tissues or cells collected from the body of an organism are fixed, or a culture solution of cells, and the like.
- an in situ hybridization method is preferably used.
- the in situ hybridization method has been developed as a method for confirming the presence or distribution of specific DNA or RNA in cells or tissues and the intensity of its expression. In principle, this utilizes the property that a probe nucleic acid having a base sequence complementary to a specific nucleic acid sequence in a cell specifically forms a complex.
- RI radioisotope
- hapten antigenic substance
- an RI label can be preferably used.
- a fluorescent label using a non-radioactive material such as biotin or hapten such as digoxigenin can be used.
- a detection method by fluorescence in situ hybridization called FISH is used.
- the cancer to be diagnosed can include clear cell adenocarcinoma among ovarian cancers. In the present invention, both primary lesions and metastatic lesions of these cancers can be diagnosed.
- any animal species that expresses LGR7 protein can be the subject.
- many mammals other than humans such as mice, rats, rhesus monkeys, and chimpanzees express LGR7.
- a particularly suitable subject is a human.
- the LGR7 mRNA of the animal species is detected.
- a sample is prepared from a subject.
- LGR7 mRNA contained in the sample is detected.
- cDNA synthesized from mRNA can also be detected.
- LGR7 mRNA or cDNA encoding LGR7 is detected in a test sample, it is determined that there is a possibility of cancer. For example, if the amount of LGR7 mRNA or cDNA encoding LGR7 detected in a test sample is higher than that in a negative control or healthy subject, the subject has cancer or will suffer from future cancer. It is shown that there is a high probability of doing. Methods for detecting mRNA are known.
- Northern blotting method for example, Northern blotting method, RT-PCR method, DNA array method and the like can be used in the present invention.
- the detection method of the present invention described above can also be automated using various automatic inspection apparatuses. By automation, a large number of samples can be inspected in a short time.
- the present invention also provides a diagnostic agent or kit for diagnosing cancer, comprising a reagent for detecting LGR7 protein in a test sample.
- the diagnostic agent of the present invention contains at least an anti-LGR7 antibody.
- a kit for diagnosing cancer can be obtained. That is, the present invention includes a kit for diagnosing cancer, which comprises an antibody that binds to LGR7, a reagent for detecting the binding between the antibody and LGR7, and may further comprise a control sample comprising a biological sample containing LGR7.
- the kit of the present invention may further include instructions for explaining the measurement operation. It should be noted that all prior art documents cited in the present specification are incorporated herein by reference.
- Example 1 Human LGR7 mRNA expression analysis using Affymetrix U133 Plus2.0 Array Total RNA was collected from 10 ovarian cancer surgical specimens collected and cryopreserved after obtaining written consent at the University of Tokyo Hospital (Japan). Extracted. In that case, the surgical specimen was embedded in an OCT compound, and the sliced piece was dissolved in TRIZOL (Invitrogen), and then total RNA was extracted according to the method attached to the product. At the same time, an HE-stained specimen was prepared and confirmed to contain a cancerous part.
- TRIZOL Invitrogen
- the histological breakdown of 10 cases of ovarian cancer is clear cell adenocarcinoma 4 cases, serous adenocarcinoma 2 cases, endometrioid adenocarcinoma 3 cases, and carcinosarcoma 1 case.
- expression analysis was performed with Affymetrix U133 Plus2.0 Array, and genes that specifically expressed high in ovarian clear cell adenocarcinoma were selected.
- the total RNA derived from normal tissues (Clontech) and ovarian cancer cell lines (ATCC, JCRB, purchased from RIKEN) was used as the target.
- At least one out of four cases of ovarian clear cell adenocarcinoma was narrowed down to the 11761 probe set whose expression value was 200 or more.
- the third highest expression level among the 4 cases of ovarian clear cell adenocarcinoma and the highest level in normal ovary, peripheral blood, bone marrow, and major tissues (liver, kidney, lung, stomach, intestine, pancreas) The values were compared and further narrowed down to 197 probe sets with a ratio of 1.8 or more.
- FIG. 1 shows a graph of signal values of ovarian cancer, ovarian cancer cell line, and normal tissue of LGR7 probe 1552715_a_at. Details of sample names are shown in Table 1. LGR7 is specifically expressed in clear cell adenocarcinoma among ovarian cancers, and antitumor agents targeting human LGR7 against this cancer type are expected to be effective.
- the DG44 cell line a Chinese hamster ovary-derived cell, was transfected with a BioRad® GenePulser to obtain an HA-LGR7-expressing cell line HA-LGR7 / DG # 24. It was introduced into Ba / F3 which is a mouse pro-B cell to obtain HA-LGR7 expressing cell line HA-LGR / BaF3 # 48. The expression of LGR7 was confirmed by Western blot using antibody HA-7 (Sigma) against HA tag (FIG. 2).
- the expression vector pMCN is a vector in which an inserted gene can be expressed under the mouse CMV promoter (ACCESSION No. U68299) and a neomycin resistance gene is incorporated as a drug resistance marker.
- the LGR7 expression vector pMCN-LGR7 was prepared by cloning the LGR7 gene into pMCN by a conventional method.
- Example 3 Preparation of anti-LGR7 monoclonal antibody by DNA immunization
- DNA immunization was performed by gene transfer into mice by the GeneGun Particle method. The method was performed according to the BioRad manual.
- a bullet for DNA immunization was prepared by mixing 1 mm Gold particle (BioRad) and pMCN-LGR7 DNA and coating the inside of the tube.
- a 6-week-old female MRL / lpr mouse female was transfected by injecting a bullet coated with pMCN-LGR7 DNA into the skin of the abdomen using Helios GeneGun (BioRad) at a pressure of 200-300 psi.
- mice The sera of the immunized mice were compared with the reaction with LGR7 protein expressed on the cell membrane surface of HA-LGR7 / DG # 24 cells. The most reactive mouse was finally immunized and subjected to cell fusion. Three days after the final immunization, the spleen cells were removed and mixed with mouse myeloma cells P3-X63Ag8U1 (P3U1, purchased from ATCC) at a ratio of 2: 1. Cell fusion was performed by gradually adding PEG1500 (Roche Diagnostics) to produce hybridoma cells. After the PEG1500 concentration was diluted by carefully adding RPMI1640 medium (GIBCO BRL), PEG1500 was removed by centrifugation.
- the hybridoma cells are suspended in RPMI1640 medium (hereinafter, HAT medium) containing 10% FBS, 1 x HAT media supplement (SIGMA), 0.5 x BM-Condimed H1 Hybridoma cloning supplement (Roche Diagnostics). And seeded in a 96-well culture plate at 200 ⁇ L / well.
- the cell concentration at the time of seeding was diluted according to the number of P3U1 cells used, and the hybridoma cells were cultured in a HAT medium at 37 ° C. and 5% CO 2 for about one week in a 96-well culture plate. Screening for hybridomas secreting antibodies into the culture supernatant was performed by flow cytometry.
- sLGR7Fc Human Fc protein base sequence, SEQ ID NO: 95, amino acid sequence, SEQ ID NO: 96
- fusion protein obtained by PCR amplification of a fragment containing the 1-555th amino acid of LGR7 protein
- the vector was constructed to express as The resulting vector was introduced into DG44 cells, and cells capable of expressing the sLGR7Fc fusion protein were selected as neomycin resistant strains.
- the obtained cell line was cultured in large quantities, and the culture supernatant was collected to purify the sLGR7Fc protein.
- the sLGR7Fc protein affinity-purified as an Fc fusion protein by rProteinA column was used as a protein immunization antigen or a hybridoma screening antigen.
- Example 5 Preparation of anti-LGR7 antibody by sLGR7Fc protein immunization 50 ⁇ g of affinity-purified sLGR7Fc protein was mixed with Freund's complete adjuvant and immunized subcutaneously in mice. In addition, mice were immunized subcutaneously with a mixture of 50 ⁇ g affinity purified sLGR7Fc protein and Freund's incomplete adjuvant twice to induce antibodies, and 25 ⁇ g sLGR7Fc protein was given to mice that had the highest reactivity with LGR7 protein.
- mice Three days after injection from the tail vein, the spleen was taken out of the mouse and subjected to cell fusion with the mouse myeloma cell line P3X63Ag8U.1, and a hybridoma was prepared in the same manner as in [Example 3].
- Example 6 Evaluation of binding activity by FACS (flow cytometry) Using the obtained hybridoma, binding to human LGR7 / DG44 cells was evaluated by flow cytometry.
- Human LGR7-expressing cell line suspended in FACS buffer (2% FBS / PBS / 0.05% NaN 3 ) was diluted to 1 ⁇ 10 6 cells / mL using FACS buffer, and then 50 ⁇ L in a Falcon 353910 round bottom 96-well plate / Dispensed in wells. The culture supernatant of the hybridoma diluted to an appropriate concentration was added to the well containing the cells and allowed to react on ice for 60 minutes. The cells were then washed once with FACS buffer.
- Example 7 Measurement of ADCC activity of anti-LGR7 monoclonal antibody ADCC activity against LGR7 forced-expressing DG44 cells in the anti-human LGR7 monoclonal antibody was examined by a chromium release method.
- the target cells are cultured for several hours in a culture solution (CHO-S SFM II (Invitrogen)) supplemented with Chromium-51, then the culture solution is removed, the cells are washed with the culture solution, and then added to a new culture solution. Suspended cells were added to a 96 well round bottom plate so that there were 1 ⁇ 10 4 cells per well.
- CHO-S SFM II Invitrogen
- NK-92 ATCC, CRL-2407
- Recombinant cells (WO2008 / 093688)) in which a chimeric protein containing the extracellular region of -gamma receptor 3 (NM_010188) and the transmembrane region and intracellular region of human gamma chain (NM_004106) were forcibly added were added.
- the plate was left at 37 ° C. for 4 hours in a 5% CO 2 incubator.
- Specific chromium release rate (%) (AC) x 100 / (BC)
- A is the radioactivity in each well
- B is the average radioactivity released into the medium after cell lysis with a final concentration of 1% Nonidet P-40
- C is the average radioactivity when only the medium is added .
- Example 8 Measurement of CDC activity of anti-LGR7 monoclonal antibody CDC activity was measured by using the degree of 7-AAD incorporation into cells in which cytotoxicity occurred as an index.
- LGR7-expressing DG44 cells and the monoclonal antibody were reacted at a concentration of 10 ⁇ g / mL for 30 minutes at 4 ° C.
- Baby Rabbit Complement (CEDARLANE LABORATORIES) was added to a final concentration of 10%, and the reaction was continued at 37 ° C. for 90 minutes.
- 7-AAD Beckman Coulter
- The% FL3 value indicates the percentage of cells that have been damaged by 7-AAD staining, and multiple anti-LGR7 antibodies are complement dependent in DG44 cells expressing HA-LGR7 as shown in FIG. Complement-dependent cytotoxicity (CDC) activity.
- Example 9 Cloning of antigen genes The sequences of antibody variable region genes were determined for 9 hybridomas of 22DA6, 22DA7, 22DA17, 22DA22, 22DA23, 22DA24, 22SD7, 22SD11, and 22SD48 that showed ADCC activity and CDC activity. .
- the antibody gene was amplified by RT-PCR using total RNA extracted from each hybridoma producing the anti-LGR7 antibody. Total RNA was extracted from 1 ⁇ 10 7 hybridoma cells using RNeasy Plant Mini Kits (QIAGEN).
- a RACE library was constructed by using SMART RACE cDNA Amplification Kit (CLONTECH) using 1 ⁇ g of total RNA.
- the antibody genes are synthetic oligonucleotides MHC-IgG1 (SEQ ID NO: 97, GGGCCAGTGGATAGACAGATG), MHC-IgG2a (SEQ ID NO: 98, CAGGGGCCAGTGGATAGACCGATG), MHC-IgG2b (SEQ ID NO: 99, CAGGGGCCAGTGGATAGACTGATG) complementary to the mouse IgG1 constant region sequence.
- a synthetic oligonucleotide kappa SEQ ID NO: 100, GCTCACTGGATGGTGGGAAGATG
- the gene fragment encoding the antibody produced by the hybridoma was amplified. .
- the reverse transcription reaction was performed at 42 ° C. for 1 hour and 30 minutes.
- 50 ⁇ L of PCR solution is 5 ⁇ L of 10 ⁇ Advantage 2 PCR Buffer, 5 ⁇ L of 10 ⁇ Universal Primer A Mix, 0.2 mM dNTPs (dATP, dGTP, dCTP, dTTP), 1 ⁇ L of Advantage 2 Polymerase Mix (above, manufactured by CLONTECH), It contained 2.5 ⁇ L of the reverse transcription reaction product and 10 pmole of synthetic oligonucleotide MHC-IgG1, MHC-IgG2a, MHC-IgG2b or kappa.
- the PCR reaction was performed at an initial temperature of 94 ° C for 30 seconds, followed by 5 cycles of 94 ° C for 5 seconds and 72 ° C for 3 minutes, then 94 ° C for 5 seconds and 70 ° C. It was performed by repeating the cycle of 10 minutes at 72 ° C for 3 minutes 5 times, and further repeating the cycle of 94 ° C for 5 seconds, 68 ° C for 10 seconds, and 72 ° C for 3 minutes 25 times. . Finally, the reaction product was heated at 72 ° C. for 7 minutes. Each PCR product was purified from an agarose gel using the QIAquick Gel Extraction Kit (QIAGEN). Subsequently, the PCR product was cloned into a pGEM-T Easy vector (Promega) and its nucleotide sequence was determined.
- the nucleotide sequence of the 22DA6 H chain variable region is shown in SEQ ID NO: 3, the amino acid sequence is shown in SEQ ID NO: 4, the nucleotide sequence of the L chain variable region is shown in SEQ ID NO: 8, and the amino acid sequence is shown in SEQ ID NO: 9.
- the amino acid sequence of the heavy chain CDR1 of 22DA6 is SEQ ID NO: 5
- the amino acid sequence of the heavy chain CDR2 is SEQ ID NO: 6
- the amino acid sequence of the heavy chain CDR3 is SEQ ID NO: 7
- the amino acid sequence of the light chain CDR1 is SEQ ID NO: 10.
- the amino acid sequence of light chain CDR2 is shown in SEQ ID NO: 11, and the amino acid sequence of light chain CDR3 is shown in SEQ ID NO: 12.
- the nucleotide sequence of the 22DA7 H chain variable region is shown in SEQ ID NO: 13
- the amino acid sequence is shown in SEQ ID NO: 14
- the nucleotide sequence of the L chain variable region is shown in SEQ ID NO: 18, and the amino acid sequence is shown in SEQ ID NO: 19.
- the amino acid sequence of the heavy chain CDR1 of 22DA7 is SEQ ID NO: 15
- the amino acid sequence of the heavy chain CDR2 is SEQ ID NO: 16
- the amino acid sequence of the heavy chain CDR3 is SEQ ID NO: 17
- the amino acid sequence of the light chain CDR1 is SEQ ID NO: 20.
- the amino acid sequence of the light chain CDR2 is shown in SEQ ID NO: 21, and the amino acid sequence of the light chain CDR3 is shown in SEQ ID NO: 22.
- the nucleotide sequence of the heavy chain variable region of 22DA17 is shown in SEQ ID NO: 23
- the amino acid sequence is shown in SEQ ID NO: 24
- the nucleotide sequence of the L chain variable region is shown in SEQ ID NO: 28
- the amino acid sequence is shown in SEQ ID NO: 29.
- the amino acid sequence of 22DA17 heavy chain CDR1 is SEQ ID NO: 25
- the amino acid sequence of heavy chain CDR2 is SEQ ID NO: 26
- the amino acid sequence of heavy chain CDR3 is SEQ ID NO: 27
- the amino acid sequence of light chain CDR1 is SEQ ID NO: 30
- the amino acid sequence of the light chain CDR2 is shown in SEQ ID NO: 31
- the amino acid sequence of the light chain CDR3 is shown in SEQ ID NO: 32.
- the nucleotide sequence of the heavy chain variable region of 22DA22 is shown in SEQ ID NO: 33, the amino acid sequence is shown in SEQ ID NO: 34, the nucleotide sequence of the L chain variable region is shown in SEQ ID NO: 38, and the amino acid sequence is shown in SEQ ID NO: 39.
- the amino acid sequence of heavy chain CDR1 of 22DA22 is SEQ ID NO: 35
- the amino acid sequence of heavy chain CDR2 is SEQ ID NO: 36
- the amino acid sequence of heavy chain CDR3 is SEQ ID NO: 37
- the amino acid sequence of light chain CDR1 is SEQ ID NO: 40.
- the amino acid sequence of light chain CDR2 is shown in SEQ ID NO: 41, and the amino acid sequence of light chain CDR3 is shown in SEQ ID NO: 42.
- the nucleotide sequence of the heavy chain variable region of 22DA23 is shown in SEQ ID NO: 43, the amino acid sequence is shown in SEQ ID NO: 44, the nucleotide sequence of the L chain variable region is shown in SEQ ID NO: 48, and the amino acid sequence is shown in SEQ ID NO: 49.
- the amino acid sequence of 22DA23 heavy chain CDR1 is SEQ ID NO: 45
- the amino acid sequence of heavy chain CDR2 is SEQ ID NO: 46
- the amino acid sequence of heavy chain CDR3 is SEQ ID NO: 47
- the amino acid sequence of light chain CDR1 is SEQ ID NO: 50
- the amino acid sequence of light chain CDR2 is shown in SEQ ID NO: 51
- the amino acid sequence of light chain CDR3 is shown in SEQ ID NO: 52.
- the nucleotide sequence of the heavy chain variable region of 22DA24 is shown in SEQ ID NO: 53, the amino acid sequence is shown in SEQ ID NO: 54, the nucleotide sequence of the L chain variable region is shown in SEQ ID NO: 58, and the amino acid sequence is shown in SEQ ID NO: 59.
- the amino acid sequence of the heavy chain CDR1 of 22DA24 is SEQ ID NO: 55, the amino acid sequence of heavy chain CDR2 is SEQ ID NO: 56, the amino acid sequence of heavy chain CDR3 is SEQ ID NO: 57, and the amino acid sequence of light chain CDR1 is SEQ ID NO: 60.
- the amino acid sequence of light chain CDR2 is shown in SEQ ID NO: 61
- the amino acid sequence of light chain CDR3 is shown in SEQ ID NO: 62
- the nucleotide sequence of the heavy chain variable region of 22SD7 is shown in SEQ ID NO: 63
- the amino acid sequence is shown in SEQ ID NO: 64
- the nucleotide sequence of the L chain variable region is shown in SEQ ID NO: 68
- the amino acid sequence is shown in SEQ ID NO: 69.
- amino acid sequence of heavy chain CDR1 of 22SD7 is SEQ ID NO: 65
- amino acid sequence of heavy chain CDR2 is SEQ ID NO: 66
- amino acid sequence of heavy chain CDR3 is SEQ ID NO: 67
- amino acid sequence of light chain CDR1 is SEQ ID NO: 70
- amino acid sequence of light chain CDR2 is shown in SEQ ID NO: 71
- amino acid sequence of light chain CDR3 is shown in SEQ ID NO: 72.
- the nucleotide sequence of the heavy chain variable region of 22SD11 is shown in SEQ ID NO: 73, the amino acid sequence is shown in SEQ ID NO: 74, the nucleotide sequence of the L chain variable region is shown in SEQ ID NO: 78, and the amino acid sequence is shown in SEQ ID NO: 79.
- amino acid sequence of heavy chain CDR1 of 22SD11 is SEQ ID NO: 75
- amino acid sequence of heavy chain CDR2 is SEQ ID NO: 76
- amino acid sequence of heavy chain CDR3 is SEQ ID NO: 77
- amino acid sequence of light chain CDR1 is SEQ ID NO: 80
- amino acid sequence of the light chain CDR2 is shown in SEQ ID NO: 81
- amino acid sequence of the light chain CDR3 is shown in SEQ ID NO: 82.
- the nucleotide sequence of the 22SD48 H chain variable region is shown in SEQ ID NO: 83, the amino acid sequence in SEQ ID NO: 84, the L chain variable region in the SEQ ID NO: 88, and the amino acid sequence in SEQ ID NO: 89.
- the amino acid sequence of the heavy chain CDR1 of 22SD48 is SEQ ID NO: 85
- the amino acid sequence of the heavy chain CDR2 is SEQ ID NO: 86
- the amino acid sequence of the heavy chain CDR3 is SEQ ID NO: 87
- the amino acid sequence of the light chain CDR1 is SEQ ID NO: 90
- the amino acid sequence of light chain CDR2 is shown in SEQ ID NO: 91
- the amino acid sequence of light chain CDR3 is shown in SEQ ID NO: 92.
- Example 10 Cytocidal effect by internaization using Mab-Zap Toxin and the like are bound to an antibody, and the antibody binds to the target cell and then is taken into the cell, and the target is activated by the action of the conjugated toxin.
- Mab-Zap manufactured by Advanced Targeting Systems
- saporin a secondary antibody conjugated with a toxin called saporin
- Example 11 Reactivity of anti-LGR7 monoclonal antibody with mouse LGR7
- Mouse LGR7 base sequence, SEQ ID NO: 93, amino acid sequence, SEQ ID NO: 94
- the cross-reactivity with mouse LGR7 was examined by flow cytometry using the forced expression cell line HA-mLGR7 / BaF3. As shown in FIG. 6, it was revealed that 22DA17 and 22DA23 showed cross-reactivity with mouse LGR7.
- Example 12 Classification of epitopes by competition FACS analysis Epitopes were classified by Competition FACS analysis. The antibody was biotinylated using Biotin Protein Labeling Kit (Roche) according to the manual. Competition FACS analysis is a method in which an excess amount of unlabeled antibody is reacted in advance and then biotinylated antibody is reacted to further detect biotinylated antibody with FITC-labeled streptavidin. In the case of antibodies recognizing the same epitope, the unlabeled antibody masks the epitope so that the biotinylated antibody cannot access the antigen, and the peak in FACS analysis shifts to the left.
- Example 13 Preparation of mouse IgG2a chimeric antibody with mouse IgG2aCH, CL
- a method for enhancing the ADCC activity of an antibody a method for modifying the sugar chain of the antibody is known.
- WO2006 / 067913 and the like it is described that an antibody having a sugar chain not containing ⁇ -1,6 core fucose is produced using a CHO cell (CHO_FTKO) in which a fucose transporter gene is knocked out.
- the antibody gene of the anti-human LGR7 monoclonal antibody 22DA23 cloned as in Example 9 was ligated to the H chain C region C ⁇ 2a and L chain C region C ⁇ of the mouse antibody by amplifying the variable regions of the H chain and L chain by PCR, respectively. Then, it was inserted into an expression vector for mammalian cells so that it could be expressed as a mouse IgG2a chimeric molecule. The resulting vector was transfected into fucose transporter-deficient CHO cells CHO_FTKO to establish neomycin-resistant strains.
- mice IgG2a chimeric antibody was purified from the culture supernatant using a Protein A column according to the manual.
- the purified antibody 22DA23-mIgG2a / FTPKO was subjected to a drug efficacy test using a mouse xenograft model.
- Example 14 Drug efficacy test using mouse xenograft model
- the purified 22DA23-mIgG2a / FTPKO (FTKODA23) antibody was subjected to a drug efficacy test in mice.
- a 7-week-old Scid female mouse (Claire Japan) was transplanted subcutaneously with RMG-1 vivo passaged tumor, approximately 3 mm square 1 piece, and grouped by tumor volume and body weight 10 days after transplantation and used for the experiment.
- RMG-1 in vivo tumors were obtained by transplanting RMG-1 cultured cells subcutaneously at 1e7 cells / body and excising the tumor 42 days later.
- mice Six mice were administered as a group, and FTKODA23 antibody was administered once a week at 2 mg / kg and 10 mg / kg.
- PBS (-) was administered to the control group.
- the first administration was performed 10 days after transplantation, the second administration after 17 days, the third administration after 24 days, and the fourth administration after 31 days.
- the tumor volume was measured twice a week, the final measurement was performed one week after the fourth administration, and the change of the tumor volume in a graph is shown in FIG.
- the tumor volume was compared between the control group and the antibody administration group.
- TGI Tuor Growth Inhibition
- the anti-LGR7 antibody of the present invention can exert an anticancer action on LGR7-expressing cells by antibody-dependent cytotoxic activity, complement-dependent cytotoxic activity, etc., and a toxin (cytotoxic substance) ) Is also useful for diagnosis, prevention and treatment of various primary or metastatic cancers.
- the antibody specific for the LGR7 protein according to the present invention is specifically expressed in clear cell adenocarcinoma among ovarian cancers and can be used as a diagnostic agent for clear cell adenocarcinoma.
- the diagnostic agent according to the present invention is useful for diagnosis of primary or metastatic cancer. Specifically, the possibility of cancer can be determined by detecting LGR7 protein contained in a biological sample collected from a patient. Alternatively, the presence of ovarian clear cell adenocarcinoma can be detected in vivo by detecting the localization of LGR7-expressing cells in vivo.
- the anti-LGR7 antibody having cytotoxic activity according to the present invention is useful for the treatment or prevention of cancer expressing LGR7 protein.
- a cytotoxic agent or cytostatic agent for cancer cells of ovarian clear cell adenocarcinoma is provided.
- the cytotoxic agent or cytostatic agent for cancer cells according to the present invention can be applied to both primary and metastatic cancers.
- the anti-LGR7 antibody having cytotoxic activity according to the present invention can be used as a therapeutic agent for ovarian clear cell adenocarcinoma.
- the anti-LGR7 antibody is useful as a therapeutic agent for both primary and metastatic cancers.
- the gene encoding the antibody according to the present invention and the recombinant cell transformed with the gene can be used to produce a recombinant antibody that exhibits the above-described effects or more preferable effects. .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
また、本発明者らはLGR7タンパク質に対するモノクローナル抗体を作成した。
さらに本発明者らは、抗LGR7抗体の抗体依存性細胞傷害(antibody-dependent cell-mediated cytotoxicity; ADCC)活性を測定したところ、抗LGR7抗体はLGR7発現細胞に対してADCC活性を有することを見出した。さらに、補体依存性の細胞傷害 (complement-dependent cell-mediated cytotoxicity; CDC)活性を測定したところ、抗LGR7抗体はLGR7発現細胞に対してCDC活性を有することも見出した。さらに、抗当該LGR7抗体を異種移植腫瘍モデルマウスに投与したところ、腫瘍縮小効果を示すことが明らかとなった。以上の知見により、本発明者らは、抗LGR7抗体が、原発性の、あるいは転移性の卵巣明細胞腺癌の診断、予防および治療に有効であることを見出して、本発明を完成させた。より具体的には、本発明者らは、抗LGR7抗体が、卵巣明細胞腺癌をはじめとする、LGR7が発現亢進している癌の、治療あるいは診断のためのツールとして有用であることを見出して本発明を完成した。
〔1〕LGR7タンパク質に結合し、かつLGR7タンパク質を発現する細胞に対して細胞増殖阻害活性を有する抗体。
〔2〕細胞増殖阻害活性が細胞傷害活性である〔1〕に記載の抗体。
〔3〕前記細胞傷害活性が抗体依存性細胞傷害活性である〔2〕に記載の抗体。
〔4〕前記細胞傷害活性が補体依存性細胞傷害活性である〔2〕 に記載の抗体。
〔5〕細胞傷害性物質が結合した抗体である〔1〕~〔4〕いずれかに記載の抗体。
〔6〕インターナライズ活性を有する抗体である〔5〕に記載の抗体。
〔7〕癌細胞の増殖を抑制する抗体である〔1〕から〔6〕のいずれかに記載の抗体。
〔8〕前記癌細胞が卵巣癌明細胞である〔7〕に記載の抗体。
〔9〕 以下(1)から(29)のいずれかに記載の抗体;
(1)CDR1として配列番号:5に記載のアミノ酸配列、CDR2として配列番号:6に記載のアミノ酸配列、およびCDR3として配列番号:7に記載のアミノ酸配列を有するH鎖を含む抗体(22DA6重鎖)、
(2)CDR1として配列番号:10に記載のアミノ酸配列、CDR2として配列番号:11に記載のアミノ酸配列、およびCDR3として配列番号:12に記載のアミノ酸配列を有するL鎖を含む抗体(22DA6軽鎖)、
(3)(1)に記載のH鎖、および(2)に記載のL鎖を含む抗体(22DA6)、
(4)CDR1として配列番号:15に記載のアミノ酸配列、CDR2として配列番号:16に記載のアミノ酸配列、およびCDR3として配列番号:17に記載のアミノ酸配列を有するH鎖を含む抗体(22DA7重鎖)、
(5)CDR1として配列番号:20に記載のアミノ酸配列、CDR2として配列番号:21に記載のアミノ酸配列、およびCDR3として配列番号:22に記載のアミノ酸配列を有するL鎖を含む抗体(22DA7軽鎖)、
(6)(4)に記載のH鎖、および(5)に記載のL鎖を含む抗体(22DA7)、
(7)CDR1として配列番号:25に記載のアミノ酸配列、CDR2として配列番号:26に記載のアミノ酸配列、およびCDR3として配列番号:27に記載のアミノ酸配列を有するH鎖を含む抗体(22DA17重鎖)、
(8)CDR1として配列番号:30に記載のアミノ酸配列、CDR2として配列番号:31に記載のアミノ酸配列、およびCDR3として配列番号:32に記載のアミノ酸配列を有するL鎖を含む抗体(22DA17軽鎖)、
(9)(7)に記載のH鎖、および(8)に記載のL鎖を含む抗体(22DA17)、
(10)CDR1として配列番号:35に記載のアミノ酸配列、CDR2として配列番号:36に記載のアミノ酸配列、およびCDR3として配列番号:37に記載のアミノ酸配列を有するH鎖を含む抗体(22DA22重鎖)、
(11)CDR1として配列番号:40に記載のアミノ酸配列、CDR2として配列番号:41に記載のアミノ酸配列、およびCDR3として配列番号:42に記載のアミノ酸配列を有するL鎖を含む抗体(22DA22軽鎖)、
(12)(10)に記載のH鎖、および(11)に記載のL鎖を含む抗体(22DA22)、
(13)CDR1として配列番号:45に記載のアミノ酸配列、CDR2として配列番号:46に記載のアミノ酸配列、およびCDR3として配列番号:47に記載のアミノ酸配列を有するH鎖を含む抗体(22DA23重鎖)、
(14)CDR1として配列番号:50に記載のアミノ酸配列、CDR2として配列番号:51に記載のアミノ酸配列、およびCDR3として配列番号:52に記載のアミノ酸配列を有するL鎖を含む抗体(22DA23軽鎖)、
(15)(13)に記載のH鎖、および(14)に記載のL鎖を含む抗体(22DA23)、
(16)CDR1として配列番号:55に記載のアミノ酸配列、CDR2として配列番号:56に記載のアミノ酸配列、およびCDR3として配列番号:57に記載のアミノ酸配列を有するH鎖を含む抗体(22DA24重鎖)、
(17)CDR1として配列番号:60に記載のアミノ酸配列、CDR2として配列番号:61に記載のアミノ酸配列、およびCDR3として配列番号:62に記載のアミノ酸配列を有するL鎖を含む抗体(22DA24軽鎖)、
(18)(16)に記載のH鎖、および(17)に記載のL鎖を含む抗体(22DA24)、
(19)CDR1として配列番号:65に記載のアミノ酸配列、CDR2として配列番号:66に記載のアミノ酸配列、およびCDR3として配列番号:67に記載のアミノ酸配列を有するH鎖を含む抗体(22SD7重鎖)、
(20)CDR1として配列番号:70に記載のアミノ酸配列、CDR2として配列番号:71に記載のアミノ酸配列、およびCDR3として配列番号:72に記載のアミノ酸配列を有するL鎖を含む抗体(22SD7軽鎖)、
(21)(19)に記載のH鎖、および(20)に記載のL鎖を含む抗体(22SD7)、
(22)CDR1として配列番号:75に記載のアミノ酸配列、CDR2として配列番号:76に記載のアミノ酸配列、およびCDR3として配列番号:77に記載のアミノ酸配列を有するH鎖を含む抗体(22SD11重鎖)、
(23)CDR1として配列番号:80に記載のアミノ酸配列、CDR2として配列番号:81に記載のアミノ酸配列、およびCDR3として配列番号:82に記載のアミノ酸配列を有するL鎖を含む抗体(22SD11軽鎖)、
(24)(22)に記載のH鎖、および(23)に記載のL鎖を含む抗体(22SD11)、
(25)CDR1として配列番号:85に記載のアミノ酸配列、CDR2として配列番号:86に記載のアミノ酸配列、およびCDR3として配列番号:87に記載のアミノ酸配列を有するH鎖を含む抗体(22SD48重鎖)、
(26)CDR1として配列番号:90に記載のアミノ酸配列、CDR2として配列番号:91に記載のアミノ酸配列、およびCDR3として配列番号:92に記載のアミノ酸配列を有するL鎖を含む抗体(22SD48軽鎖)、
(27)(25)に記載のH鎖、および(26)に記載のL鎖を含む抗体(22SD48)、
(28)(1)~(27)いずれかに記載の抗体と同等の活性を有する抗体、
(29)(1)~(27)いずれかに記載の抗体が認識するエピトープと同一のエピトープを認識する抗体。
〔10〕ヒト定常領域を有する抗体である〔1〕~〔9〕のいずれかに記載の抗体。
〔11〕 キメラ抗体、ヒト化抗体またはヒト抗体である〔10〕に記載の抗体。
〔12〕フコースが欠損した抗体である〔1〕~〔11〕のいずれかに記載の抗体。
〔13〕〔1〕から〔12〕のいずれかに記載の抗体を有効成分として含有する医薬組成物。
〔14〕〔1〕から〔12〕のいずれかに記載の抗体を有効成分として含有する細胞増殖抑制剤。
〔15〕〔1〕から〔12〕のいずれかに記載の抗体を有効成分として含有する抗癌剤。
〔16〕治療対象となる癌が卵巣癌である、〔15〕に記載の抗癌剤。
〔17〕前記卵巣癌が明細胞腺癌である〔16〕に記載の抗癌剤。
〔18〕LGR7タンパク質またはLGR7タンパク質をコードする遺伝子を検出することを特徴とする癌の診断方法。
〔19〕LGR7タンパク質を検出することを特徴とする癌の診断方法。
〔20〕LGR7タンパク質の検出がLGR7タンパク質に結合する抗体を用いて行なわれる〔19〕に記載の診断方法。
〔21〕以下の工程を含む癌の診断方法;
(a) 被検者から採取された試料を提供する工程、
(b) (a)の試料に含まれるLGR7タンパク質を、LGR7タンパク質に結合する抗体を用いて検出する工程。
〔22〕以下の工程を含む癌の診断方法;
(a) LGR7タンパク質への結合活性を有し、かつ放射性同位元素で標識された抗体を被検者に投与する工程、
(b) 前記放射性同位元素の集積を検出する工程。
〔23〕診断対象となる癌が卵巣癌である〔18〕から〔22〕のいずれかに記載の診断方法。
〔24〕前記卵巣癌が明細胞腺癌である〔23〕に記載の診断方法。
本発明においてLGR7は、7回膜貫通型のLGRファミリーメンバーであるタンパク質である。ヒトLGR7のアミノ酸配列およびこれをコードする遺伝子配列は、それぞれNCBI登録番号NP_067647(配列番号:1)及びNM_021634(配列番号:2)に開示されている。また、本発明で用いられるLGR7はスプライシングバリアントや変異体であってもよい。本発明において、LGR7タンパク質とは、全長タンパク質およびその断片の両方を含むことを意味する。断片とは、LGR7タンパク質の任意の領域を含むポリペプチドであり、天然のLGR7タンパク質の機能を有していなくてもよい。断片の例として、LGR7タンパク質の細胞外領域を含む断片が挙げられる。LGR7タンパク質の細胞外領域は配列番号:1のアミノ酸配列において1-404番目、462-485番目、549-581番目、および648-661番目が相当する。又、膜貫通領域は配列番号:1のアミノ酸配列において405-427番目、439-461番目、486-508番目、529-548番目、582-604番目、625-647番目、および662-681番目が相当する。
本発明で用いられる抗LGR7抗体は、LGR7タンパク質に結合すればよく、その由来、種類、形状などは問われない。具体的には、非ヒト動物の抗体(例えば、マウス抗体、ラット抗体、ラクダ抗体)、ヒト抗体、キメラ抗体、ヒト化抗体などの公知の抗体が使用できる。本発明においては、モノクローナル、あるいはポリクローナルを抗体として利用することができるが好ましくはモノクローナル抗体である。抗体のLGR7タンパク質への結合は特異的な結合であることが好ましい。又、本発明で用いられる抗LGR7抗体がヒトLGR7を認識する抗体である場合、ヒトLGR7を特異的に認識する抗体であってもよいし、他の動物由来のLGR7(例えば、マウスLGR7)を同時に認識する抗体であってもよい。
ヒトLGR7のアミノ酸配列に基づいて化学合成によって取得されたペプチド
LGR7遺伝子の一部を発現ベクターに組込んで発現させることによって取得されたペプチド
LGR7タンパク質をタンパク質分解酵素により分解することによって取得されたペプチド
-LGR7のような膜蛋白質の構造を維持して免疫刺激を与えることができる
-免疫抗原を精製する必要が無い
P3(P3x63Ag8.653)(J. Immunol.(1979)123, 1548-1550)
P3x63Ag8U.1(Current Topics in Microbiology and Immunology(1978)81, 1-7)
NS-1(Kohler. G. and Milstein, C. Eur. J. Immunol.(1976)6, 511-519)
MPC-11(Margulies. D.H. et al., Cell(1976)8, 405-415)
SP2/0(Shulman, M. et al., Nature(1978)276, 269-270)
FO(de St. Groth, S. F. etal., J. Immunol. Methods(1980)35, 1-21)
S194(Trowbridge, I. S. J. Exp. Med.(1978)148, 313-323)
R210(Galfre, G. et al., Nature(1979)277, 131-133)等
このようにして作製されるモノクローナル抗体を産生するハイブリドーマは、通常の培養液中で継代培養することができる。また、該ハイブリドーマを液体窒素中で長期にわたって保存することもできる。
グアニジン超遠心法(Chirgwin, J. M. et al., Biochemistry(1979)18, 5294-5299)
AGPC法(Chomczynski, P.et al., Anal. Biochem.(1987)162, 156-159)
(1) 得られたcDNAによってコードされるV領域を含む抗体をLGR7に接触させる工程、
(2) LGR7と抗体との結合を検出する工程、および
(3) LGR7に結合する抗体を選択する工程
(1)哺乳類細胞:CHO、COS、ミエローマ、BHK(baby hamster kidney)、Hela、Vero、HEK293、Ba/F3、HL-60、Jurkat、SK-HEP1など
(2)両生類細胞:アフリカツメガエル卵母細胞など
(3)昆虫細胞:sf9、sf21、Tn5など
酵母:サッカロミセス・セレビシエ(Saccharomyces serevisiae)などのサッカロミセス(Saccharomyces )属、メタノール資化酵母(Pichia pastoris)などのPichia属
糸状菌:アスペスギルス・ニガー(Aspergillus niger)などのアスペルギルス(Aspergillus)属
アミノグリコシドトランスフェラーゼ(APH)遺伝子
チミジンキナーゼ(TK)遺伝子
大腸菌キサンチングアニンホスホリボシルトランスフェラーゼ(Ecogpt)遺伝子
ジヒドロ葉酸還元酵素(dhfr)遺伝子等
従って、本発明で用いられる抗体の好ましい態様の一つとして、ヒト定常領域を有する抗体を挙げることができる。
パパイン消化:F(ab)2またはFab
ペプシン消化:F(ab’)2またはFab’
プラスミン消化:Facb
抗体のH鎖またはH鎖V領域をコードするDNA配列、および
抗体のL鎖またはL鎖V領域をコードするDNA配列
sc(Fv)2は、2つのVH及び2つのVLをリンカー等で結合して一本鎖にした低分子化抗体である(Hudson et al、J Immunol. Methods 1999;231:177-189)。sc(Fv)2は、例えば、scFvをリンカーで結ぶことによって作製できる。
2つのVHと2つのVLの順序は特に上記配置に限定されず、どのような順序で並べられていてもよい。例えば以下のような配置も挙げることができる。
[VL]リンカー[VH]リンカー[VH]リンカー[VL]
[VH]リンカー[VL]リンカー[VL]リンカー[VH]
[VH]リンカー[VH]リンカー[VL]リンカー[VL]
[VL]リンカー[VL]リンカー[VH]リンカー[VH]
[VL]リンカー[VH]リンカー[VL]リンカー[VH]
Ser
Gly・Ser
Gly・Gly・Ser
Ser・Gly・Gly
Gly・Gly・Gly・Ser(配列番号:101)
Ser・Gly・Gly・Gly(配列番号:102)
Gly・Gly・Gly・Gly・Ser(配列番号:103)
Ser・Gly・Gly・Gly・Gly(配列番号:104)
Gly・Gly・Gly・Gly・Gly・Ser(配列番号:105)
Ser・Gly・Gly・Gly・Gly・Gly(配列番号:106)
Gly・Gly・Gly・Gly・Gly・Gly・Ser(配列番号:107)
Ser・Gly・Gly・Gly・Gly・Gly・Gly(配列番号:108)
(Gly・Gly・Gly・Gly・Ser(配列番号:101))n
(Ser・Gly・Gly・Gly・Gly(配列番号:102))n
[nは1以上の整数である]
[VH]ペプチドリンカー(15アミノ酸)[VL]ペプチドリンカー(15アミノ酸)[VH]ペプチドリンカー(15アミノ酸)[VL]
N-ヒドロキシスクシンイミド(NHS)、
ジスクシンイミジルスベレート(DSS)、
ビス(スルホスクシンイミジル)スベレート(BS3)、
ジチオビス(スクシンイミジルプロピオネート)(DSP)、
ジチオビス(スルホスクシンイミジルプロピオネート)(DTSSP)、
エチレングリコールビス(スクシンイミジルスクシネート)(EGS)、
エチレングリコールビス(スルホスクシンイミジルスクシネート)(スルホ-EGS)、
ジスクシンイミジル酒石酸塩(DST)、ジスルホスクシンイミジル酒石酸塩(スルホ-DST)、
ビス[2-(スクシンイミドオキシカルボニルオキシ)エチル]スルホン(BSOCOES)、および
ビス[2-(スルホスクシンイミドオキシカルボニルオキシ)エチル]スルホン(スルホ-BSOCOES)など
グリコシル化が修飾された抗体(WO99/54342など)、
糖鎖に付加するフコースが欠損した抗体(WO00/61739、WO02/31140、WO2006/067913など))、
バイセクティングGlcNAcを有する糖鎖を有する抗体(WO02/79255など)など。
本発明における細胞傷害活性としては、例えば抗体依存性細胞介在性細胞傷害(antibody-dependent cell-mediated cytotoxicity:ADCC)活性、補体依存性細胞傷害(complement-dependent cytotoxicity:CDC)活性などを挙げることができる。本発明において、CDC活性とは補体系による細胞傷害活性を意味する。一方ADCC活性とは標的細胞の細胞表面抗原に特異的抗体が付着した際、そのFc部分にFcγ受容体保有細胞(免疫細胞等)がFcγ受容体を介して結合し、標的細胞に傷害を与える活性を意味する。
(1)エフェクター細胞の調製
CBA/Nマウスなどから脾臓を摘出し、RPMI1640培地(Invitrogen社製)中で脾臓細胞が分離される。10%ウシ胎児血清(FBS、HyClone社製)を含む同培地で洗浄後、細胞濃度を5×106/mlに調製することによって、エフェクター細胞が調製できる。
(2)補体溶液の調製
Baby Rabbit Complement(CEDARLANE社製)を10% FBS含有培地(Invitrogen社製)にて10倍希釈し、補体溶液が調製できる。
(3)標的細胞の調製
LGR7タンパク質を発現する細胞を0.2 mCiの51Cr-クロム酸ナトリウム(GEヘルスケアバイオサイエンス社製)とともに、10% FBS含有DMEM培地中で37℃にて1時間培養することにより該標的細胞を放射性標識できる。LGR7タンパク質を発現する細胞としては、LGR7タンパク質をコードする遺伝子で形質転換された細胞、卵巣癌等を利用することができる。放射性標識後、細胞を10% FBS含有RPMI1640培地にて3回洗浄し、細胞濃度を2×105/mlに調製することによって、該標的細胞が調製できる。
インターナライズ活性を有する抗体は例えば上述の細胞傷害性物質を結合することにより抗癌剤などの医薬組成物として用いることができる。
(1)CDR1として配列番号:5に記載のアミノ酸配列、CDR2として配列番号:6に記載のアミノ酸配列、およびCDR3として配列番号:7に記載のアミノ酸配列を有するH鎖を含む抗体(22DA6重鎖)、
(2)CDR1として配列番号:10に記載のアミノ酸配列、CDR2として配列番号:11に記載のアミノ酸配列、およびCDR3として配列番号:12に記載のアミノ酸配列を有するL鎖を含む抗体(22DA6軽鎖)、
(3)(1)に記載のH鎖、および(2)に記載のL鎖を含む抗体(22DA6)、
(4)CDR1として配列番号:15に記載のアミノ酸配列、CDR2として配列番号:16に記載のアミノ酸配列、およびCDR3として配列番号:17に記載のアミノ酸配列を有するH鎖を含む抗体(22DA7重鎖)、
(5)CDR1として配列番号:20に記載のアミノ酸配列、CDR2として配列番号:21に記載のアミノ酸配列、およびCDR3として配列番号:22に記載のアミノ酸配列を有するL鎖を含む抗体(22DA7軽鎖)、
(6)(4)に記載のH鎖、および(5)に記載のL鎖を含む抗体(22DA7)、
(7)CDR1として配列番号:25に記載のアミノ酸配列、CDR2として配列番号:26に記載のアミノ酸配列、およびCDR3として配列番号:27に記載のアミノ酸配列を有するH鎖を含む抗体(22DA17重鎖)、
(8)CDR1として配列番号:30に記載のアミノ酸配列、CDR2として配列番号:31に記載のアミノ酸配列、およびCDR3として配列番号:32に記載のアミノ酸配列を有するL鎖を含む抗体(22DA17軽鎖)、
(9)(7)に記載のH鎖、および(8)に記載のL鎖を含む抗体(22DA17)、
(10)CDR1として配列番号:35に記載のアミノ酸配列、CDR2として配列番号:36に記載のアミノ酸配列、およびCDR3として配列番号:37に記載のアミノ酸配列を有するH鎖を含む抗体(22DA22重鎖)、
(11)CDR1として配列番号:40に記載のアミノ酸配列、CDR2として配列番号:41に記載のアミノ酸配列、およびCDR3として配列番号:42に記載のアミノ酸配列を有するL鎖を含む抗体(22DA22軽鎖)、
(12)(10)に記載のH鎖、および(11)に記載のL鎖を含む抗体(22DA22)、
(13)CDR1として配列番号:45に記載のアミノ酸配列、CDR2として配列番号:46に記載のアミノ酸配列、およびCDR3として配列番号:47に記載のアミノ酸配列を有するH鎖を含む抗体(22DA23重鎖)、
(14)CDR1として配列番号:50に記載のアミノ酸配列、CDR2として配列番号:51に記載のアミノ酸配列、およびCDR3として配列番号:52に記載のアミノ酸配列を有するL鎖を含む抗体(22DA23軽鎖)、
(15)(13)に記載のH鎖、および(14)に記載のL鎖を含む抗体(22DA23)、
(16)CDR1として配列番号:55に記載のアミノ酸配列、CDR2として配列番号:56に記載のアミノ酸配列、およびCDR3として配列番号:57に記載のアミノ酸配列を有するH鎖を含む抗体(22DA24重鎖)、
(17)CDR1として配列番号:60に記載のアミノ酸配列、CDR2として配列番号:61に記載のアミノ酸配列、およびCDR3として配列番号:62に記載のアミノ酸配列を有するL鎖を含む抗体(22DA24軽鎖)、
(18)(16)に記載のH鎖、および(17)に記載のL鎖を含む抗体(22DA24)、
(19)CDR1として配列番号:65に記載のアミノ酸配列、CDR2として配列番号:66に記載のアミノ酸配列、およびCDR3として配列番号:67に記載のアミノ酸配列を有するH鎖を含む抗体(22SD7重鎖)、
(20)CDR1として配列番号:70に記載のアミノ酸配列、CDR2として配列番号:71に記載のアミノ酸配列、およびCDR3として配列番号:72に記載のアミノ酸配列を有するL鎖を含む抗体(22SD7軽鎖)、
(21)(19)に記載のH鎖、および(20)に記載のL鎖を含む抗体(22SD7)、
(22)CDR1として配列番号:75に記載のアミノ酸配列、CDR2として配列番号:76に記載のアミノ酸配列、およびCDR3として配列番号:77に記載のアミノ酸配列を有するH鎖を含む抗体(22SD11重鎖)、
(23)CDR1として配列番号:80に記載のアミノ酸配列、CDR2として配列番号:81に記載のアミノ酸配列、およびCDR3として配列番号:82に記載のアミノ酸配列を有するL鎖を含む抗体(22SD11軽鎖)、
(24)(22)に記載のH鎖、および(23)に記載のL鎖を含む抗体(22SD11)、
(25)CDR1として配列番号:85に記載のアミノ酸配列、CDR2として配列番号:86に記載のアミノ酸配列、およびCDR3として配列番号:87に記載のアミノ酸配列を有するH鎖を含む抗体(22SD48重鎖)、
(26)CDR1として配列番号:90に記載のアミノ酸配列、CDR2として配列番号:91に記載のアミノ酸配列、およびCDR3として配列番号:92に記載のアミノ酸配列を有するL鎖を含む抗体(22SD48軽鎖)、
(27)(25)に記載のH鎖、および(26)に記載のL鎖を含む抗体(22SD48)、
(28)(1)~(27)いずれかに記載の抗体と同等の活性を有する抗体、
(29)(1)~(27)いずれかに記載の抗体が認識するエピトープと同一のエピトープを認識する抗体
このような変異体における、変異するアミノ酸数は、通常、50アミノ酸以内であり、好ましくは30アミノ酸以内であり、さらに好ましくは10アミノ酸以内(例えば、5アミノ酸以内)である。
疎水性アミノ酸(A、I、L、M、F、P、W、Y、V)、
親水性アミノ酸(R、D、N、C、E、Q、G、H、K、S、T)、
脂肪族側鎖を有するアミノ酸(G、A、V、L、I、P)、
水酸基含有側鎖を有するアミノ酸(S、T、Y)、
硫黄原子含有側鎖を有するアミノ酸(C、M)、
カルボン酸及びアミド含有側鎖を有するアミノ酸(D、N、E、Q)、
塩基含有側鎖を有するアミノ酸(R、K、H)、
芳香族含有側鎖を有するアミノ酸(H、F、Y、W)
(括弧内はいずれもアミノ酸の一文字標記を表す)
具体的には、競合ELISAアッセイにおいてマイクロタイタープレートのウェルにコーティングするLGR7タンパク質のかわりにLGR7タンパク質を発現した細胞を用いる。候補の競合抗体の存在下、または非存在下でプレインキュベートした後にビオチンで標識した本発明の抗LGR7抗体を添加し、ストレプトアビジンフルオロセインコンジュゲートを使用することにより抗体間の競合が測定できる。フローサイトメトリーを利用した交叉ブロッキングアッセイを、特に競合FACSアッセイと言う。抗体は、検出あるいは測定が可能な他の蛍光標識物質で標識することができる。
別の観点においては、本発明は、LGR7タンパク質に結合する抗体を有効成分として含有する医薬組成物を提供する。又、本発明はLGR7タンパク質に結合する抗体を有効成分として含有する細胞増殖抑制剤、特に抗癌剤に関する。本発明の細胞増殖抑制剤および抗癌剤は、癌を罹患している対象または罹患している可能性がある対象に投与されることが好ましい。LGR7の発現レベルは、脳以外の正常細胞で非常に低い一方、癌細胞では亢進していることから、抗LGR7抗体の投与によって、癌細胞特異的な細胞傷害作用が得られると考えられる。
本発明の医薬組成物(例えば、抗癌剤)において用いられる抗LGR7抗体は特に限定されず、如何なる抗LGR7抗体であってもよく、例えば上述の抗LGR7抗体を用いることができる。
本発明の医薬組成物が対象とする疾患が癌の場合、対象となる癌は特に限定されないが、卵巣癌であることが好ましく、卵巣癌明細胞腺癌が特に好ましい。癌は原発病巣および転移病巣のいずれであってもよい。
(a) 被検者から採取された試料を提供する工程、
(b) 採取された試料に含まれるLGR7タンパク質を、LGR7タンパク質に結合する抗体を用いて検出する工程。
単にLGR7タンパク質が存在するか否かの測定
LGR7タンパク質が一定の量以上存在するか否かの測定
LGR7タンパク質の量を他の試料(例えば、コントロール試料など)と比較する測定など
一方、定量的な検出とは、LGR7タンパク質の濃度の測定、LGR7タンパク質の量の測定などを挙げることができる。
(1) 被検者から採取された生体試料中のLGR7発現レベルを検出する工程、および
(2) (1)で検出されたLGR7の発現レベルが、対照と比較して高い場合に被検者が癌を有することが示される工程。
ラジオイムノアッセイ(RIA)、
エンザイムイムノアッセイ(EIA)、
蛍光イムノアッセイ(FIA)、
発光イムノアッセイ(LIA)、
免疫沈降法(IP)、
免疫比濁法(TIA)、
ウエスタンブロット(WB)、
免疫組織化学(IHC)法、
免疫拡散法(SRID)。
すなわち、LGR7は、癌細胞において特異的に発現が増強している膜タンパク質であることから、抗LGR7抗体によって、癌細胞、あるいは癌組織を検出することができる。上記の免疫組織学的な解析によって、生体から採取された細胞や組織に含まれる癌細胞が検出される。
単にLGR7のmRNAが存在するか否かの測定、
LGR7のmRNAが一定の量以上存在するか否かの測定、
LGR7のmRNAの量を他の試料(例えば、コントロール試料など)と比較する測定など
一方、定量的な検出とは、LGR7のmRNAの濃度の測定、LGR7のmRNAの量の測定などを挙げることができる。
診断される癌は、卵巣癌のうちの明細胞腺癌を挙げることができる。本発明においては、これらの癌の原発病巣、および転移病巣のいずれをも診断することができる。
mRNAを検出する方法は、公知である。具体的には、例えばノーザンブロッティング法、RT-PCR法、DNAアレイ法等を本発明に利用することができる。
上記した本発明の検出方法は、種々の自動検査装置を用いて自動化することもできる。自動化することによって、短時間に多数の試料を検査することができる。
本発明の癌の診断用試薬と、LGR7の検出に用いられるその他の要素を組み合わせることによって、癌の診断のためのキットとすることができる。すなわち本発明は、LGR7に結合する抗体と、該抗体とLGR7との結合を検出する試薬を含み、さらにLGR7を含む生体試料からなる対照試料を含んでいてもよい、癌の診断のためのキットに関する。本発明のキットには、更に測定操作を説明するための指示書をキットに添付することもできる。
なお本明細書において引用された全ての先行技術文献は、参照として本明細書に組み入れられる。
[実施例1] Affymetrix U133 Plus2.0 Arrayによるヒト LGR7 mRNA発現解析
東京大学医学部附属病院(日本)にて文書により同意を得たうえで採取、凍結保存した卵巣癌手術検体10例よりtotal RNAを抽出した。その際には、手術検体をOCTコンパウンドに包埋し、薄切したものをTRIZOL(Invitrogen社)に溶解した後、製品添付の方法に従ってtotal RNA抽出を行った。また同時にHE染色標本を作成し、癌部が含まれていることを確認した。卵巣癌10例の組織型の内訳は、明細胞腺癌4例、漿液性腺癌2例、類内膜腺癌3例、癌肉腫1例である。これらのtotal RNAを用いてAffymetrix U133 Plus2.0 Arrayにて発現解析を行い、卵巣明細胞腺癌に特異的に高発現を認める遺伝子を選出した。対象として正常組織(Clontech社)、卵巣癌細胞株(ATCC、JCRB、理研から購入)由来のtotalRNAを使用した。
LGR7は卵巣癌のうちでも明細胞腺癌に特異的に発現しており、この癌種に対するヒト LGR7を標的とした抗腫瘍剤が有効であることが期待される。
全長ヒトLGR7 cDNAはそれぞれNCBI登録番号NP_067647(配列番号:1(アミノ酸配列))及びNM_021634(配列番号:2(塩基配列))を基礎にしてHuman Uterus QUICK-CLONE cDNA (Clontech社)を用いてPCR法によって単離され、pGEM-T Easy (Promega社)にクローニングした後、N末端にHAタグの配列を付加した後に哺乳細胞発現用pMCN2iベクターにクローニングされた。
GeneGun Particle法によるマウスへの遺伝子導入によるDNA免疫が行われた。方法はBioRad社のマニュアルに従って実施された。1 mm Gold particle(BioRad社)とpMCN-LGR7 DNAを混合してチューブの内部にコーティングすることによりDNA免疫用の弾が作製された。6週令のMRL/lprマウスのメスに対して200-300 psiの圧力でHelios GeneGun(BioRad社)を用いてpMCN-LGR7 DNAがコーティングされた弾を腹部の皮膚に打ち込むことにより遺伝子導入した。皮膚に存在するケラチノサイト(keratinocyte)、ランゲルハンス細胞(Langerhans cell)、デンドリティック細胞(dermal dendritic cell)に導入された遺伝子はLGR7タンパク質を発現することにより、これらの細胞が抗原提示細胞(APC)となり免疫を惹起すると考えられる(Methods 31, 232-242(2003);Immunization with DNA through the skin)。DNA免疫は1週間間隔で6回行われた。最終免疫としてはLGR7を発現するBaF3細胞株HA-LGR/BaF3#48、100万個の細胞がPBSに希釈された後に尾静脈内に投与された。抗体価の測定はHA-LGR7/DG#24細胞を用いたFACS解析により実施された。免疫したマウスの血清について、HA-LGR7/DG#24細胞の細胞膜表面上に発現しているLGR7タンパク質との反応が比較された。反応性が一番高かったマウスに最終免疫して細胞融合に供された。最終免疫の3日後、当該脾臓細胞が摘出され、マウスミエローマ細胞P3-X63Ag8U1(P3U1、ATCCより購入)と2:1になるように混合された。細胞融合はPEG1500(ロシュ・ダイアグノスティック社)を徐々に加える事により行われ、ハイブリドーマ細胞が作製された。慎重にRPMI1640培地(GIBCO BRL社)を加えることによってPEG1500濃度が希釈された後、遠心操作によりPEG1500を除去した。次に、ハイブリドーマ細胞は10%FBS、1 × HAT media supplement(SIGMA社)、0.5 × BM-Condimed H1 Hybridoma cloning supplement(ロシュ・ダイアグノスティック社)を含むRPMI1640培地(以降、HAT培地)に懸濁され、200μL/ウェルとなるように96穴培養プレートに播種された。播種の際の細胞濃度は使用したP3U1細胞数に応じて希釈され、ハイブリドーマ細胞は96ウェル培養プレート中で37℃、5% CO2にてHAT培地中で約一週間培養された。培養上清中に抗体を分泌しているハイブリドーマのスクリーニングはフローサイトメトリーにより実施された。
LGR7タンパク質の1-555番目のアミノ酸を含む断片をPCRにより増幅してヒトのFc蛋白(塩基配列、配列番号:95、アミノ酸配列、配列番号:96)と融合蛋白として発現するようにベクターを構築した。できたベクターをDG44細胞に導入してsLGR7Fcの融合蛋白が発現できる細胞をネオマイシン耐性株として選抜した。得られた細胞株を大量に培養して培養上清を回収してsLGR7Fc蛋白を精製した。rProteinAカラムによりFc融合蛋白としてアフィニティー精製されたsLGR7Fc蛋白は蛋白免疫の抗原やハイブリドーマのスクリーニング抗原に供された。
アフィニティー精製sLGR7Fc蛋白は50μgをフロイント・コンプリートアジュバントと混合してマウス皮下に免疫した。さらに2回アフィニティー精製sLGR7Fc蛋白50μgとフロイント・インコンプリートアジュバントを混合したものを皮下にマウスの免疫することで抗体を誘導し、LGR7タンパク質との反応性が一番高かったマウスに25μgのsLGR7Fc蛋白を尾静脈より注射して3日後にマウスより脾臓を取り出してマウスミエローマ細胞株P3X63Ag8U.1と細胞融合に供して[実施例3]と同様にしてハイブリドーマを調製した。
得られたハイブリドーマを用い、ヒトLGR7/DG44細胞に対する結合がフローサイトメトリーにより評価された。FACSバッファー(2% FBS/PBS/0.05% NaN3)に懸濁したヒトLGR7発現細胞株はFACSバッファーを用いて1×106個/mLに希釈された後、Falcon353910丸底96ウェルプレートに50μL/ウェルで分注された。細胞の入ったウェルに適当な濃度に希釈したハイブリドーマの培養上清を加えて、氷上にて60分間反応させた。次に細胞はFACSバッファーにて1回洗浄された。細胞の入ったウェルに2次抗体としてGoat F(ab')2 フラグメント抗マウスIgG Fcγ-FITC(Beckman Coulter社)を添加した後、氷上にて30分間反応させた。反応後、遠心分離により上清が除かれた後に、FACS バッファー100μLに懸濁された細胞はフローサイトメトリーに供された。フローサイトメトリーにはFACS Calibur(ベクトンディッキンソン社)が用いられた。前方散乱光(forward scatter)及び側方散乱光(side scatter)のドットブロットにて生細胞集団にゲートが設定され、当該集団に含まれる細胞についてFL1のヒストグラムをとって結合活性が評価された。
抗ヒトLGR7モノクローナル抗体におけるLGR7強制発現DG44細胞に対するADCC活性をクロム放出法で調べた。ターゲット細胞はChromium-51を添加した培養液(CHO-S SFM II(Invitrogen社製))にて培養を数時間行った後、培養液を除去、培養液で細胞を洗浄した後に新しい培養液に懸濁された細胞が1ウェルあたり1×104個の細胞となるように96ウェル丸底プレートに添加された。続いて抗体を最終濃度1μg/mL、0.1μg/mLとなるように添加し、各ウェルにターゲット細胞に比べて約5倍量のエフェクター細胞(NK-92 (ATCC, CRL-2407)にマウスFc-gamma受容体3(NM_010188)の細胞外領域およびヒトgamma鎖(NM_004106)の膜貫通領域と細胞内領域を含むキメラタンパク質を強制発現させた組換え細胞(WO2008/093688))を添加した。プレートを5% CO2インキュベーター中で37℃にて4時間静置した。静置後プレートを遠心し、各ウェルより一定量の上清を回収してガンマカウンターWallac 1480を用いて放射活性を測定し以下の式を用いて特異的クロム遊離率(%)を求めた。
特異的クロム遊離率(%) = (A-C)×100/(B-C)
ここで、Aは各ウェルにおける放射活性、Bは終濃度1% Nonidet P-40で細胞溶解して培地へ放出される放射活性平均値、Cは培地のみ添加した場合における放射活性平均値である。
CDC活性は細胞傷害が生じた細胞への7-AADの取り込みの度合いを指標にすることによって測定された。
LGR7発現DG44細胞とモノクローナル抗体を10μg/mLの濃度で4℃にて30分間反応させた。次に、Baby Rabbit Complement(CEDARLANE LABORATORIES 社)が最終濃度10%となるように添加され、37℃で90分反応が継続された。7-AAD(Beckman Coulter社)が最終濃度1μg/mLで加えられた後に室温で10分静置された。その後、細胞はFACSバッファーで洗浄された後、細胞傷害が起きている細胞の割合がFACS Caliburにて解析された。%FL3の値は7-AADで染色された細胞傷害を受けている細胞の割合を示し、HA-LGR7を発現しているDG44細胞において図4に示すように複数の抗LGR7抗体が補体依存的細胞傷害(complement-dependent cytotoxicity(CDC))活性を示した。
ADCC活性及びCDC活性を示した22DA6、22DA7、22DA17、22DA22、22DA23、22DA24、22SD7、22SD11、22SD48の9種類のハイブリドーマについて抗体可変領域遺伝子の配列が決定された。抗体の遺伝子は、抗LGR7抗体を産生するそれぞれのハイブリドーマより抽出したTotal RNAを用いてRT-PCR法によって増幅された。Total RNAは、RNeasy Plant Mini Kits(QIAGEN社)を用いて1×107細胞のハイブリドーマより抽出された。1μgのTotal RNAを使用して、SMART RACE cDNA Amplification Kit(CLONTECH社)を用いることによってRACEライブラリーが構築された。抗体遺伝子はマウスIgG1定常領域配列に相補的な合成オリゴヌクレオチドMHC-IgG1(配列番号:97、 GGGCCAGTGGATAGACAGATG)、MHC-IgG2a(配列番号:98、CAGGGGCCAGTGGATAGACCGATG)、MHC-IgG2b(配列番号:99、 CAGGGGCCAGTGGATAGACTGATG)またはマウスκ鎖定常領域塩基配列に相補的な合成オリゴヌクレオチドkappa(配列番号:100、GCTCACTGGATGGTGGGAAGATG)を用いることによって、当該ハイブリドーマが産生する抗体をコードする遺伝子の5’末端側遺伝子断片が増幅された。逆転写反応は42℃で1時間30分間反応した。PCR溶液50μLは、5μLの10×Advantage 2 PCR Buffer、5μLの10×Universal Primer A Mix、0.2 mM dNTPs(dATP,dGTP,dCTP,dTTP)、1μLのAdvantage 2 Polymerase Mix(以上、CLONTECH社製)、2.5μLの逆転写反応産物、10 pmoleの合成オリゴヌクレオチドMHC-IgG1, MHC-IgG2a, MHC-IgG2bまたはkappaを含有していた。PCR反応は、94℃の初期温度にて30秒間反応後、94℃にて5秒間、72℃にて3分間のサイクルを5回反復し、次に94℃にて5秒間、70℃にて10秒間、72℃にて3分間のサイクルを5回反復し、さらに94℃にて5秒間、68℃にて10秒間、72℃にて3分間のサイクルを25回反復することによって行われた。最後に反応産物は72℃で7分間加熱された。各PCR産物はQIAquick Gel Extraction Kit(QIAGEN社製)を用いて、アガロースゲルから精製された。その後、当該PCR産物はpGEM-T Easyベクター(Promega社製)へクローニングされ、その塩基配列が決定された。
22DA7のH鎖可変領域の塩基配列を配列番号:13、アミノ酸配列を配列番号:14、L鎖可変領域の塩基配列を配列番号:18、アミノ酸配列を配列番号:19に示す。又、22DA7の重鎖CDR1のアミノ酸配列を配列番号:15、重鎖CDR2のアミノ酸配列を配列番号:16、重鎖CDR3のアミノ酸配列を配列番号:17、軽鎖CDR1のアミノ酸配列を配列番号:20、軽鎖CDR2のアミノ酸配列を配列番号:21、軽鎖CDR3のアミノ酸配列を配列番号:22に示す。
22DA17のH鎖可変領域の塩基配列を配列番号:23、アミノ酸配列を配列番号:24、L鎖可変領域の塩基配列を配列番号:28、アミノ酸配列を配列番号:29に示す。又、22DA17の重鎖CDR1のアミノ酸配列を配列番号:25、重鎖CDR2のアミノ酸配列を配列番号:26、重鎖CDR3のアミノ酸配列を配列番号:27、軽鎖CDR1のアミノ酸配列を配列番号:30、軽鎖CDR2のアミノ酸配列を配列番号:31、軽鎖CDR3のアミノ酸配列を配列番号:32に示す。
22DA22のH鎖可変領域の塩基配列を配列番号:33、アミノ酸配列を配列番号:34、L鎖可変領域の塩基配列を配列番号:38、アミノ酸配列を配列番号:39に示す。又、22DA22の重鎖CDR1のアミノ酸配列を配列番号:35、重鎖CDR2のアミノ酸配列を配列番号:36、重鎖CDR3のアミノ酸配列を配列番号:37、軽鎖CDR1のアミノ酸配列を配列番号:40、軽鎖CDR2のアミノ酸配列を配列番号:41、軽鎖CDR3のアミノ酸配列を配列番号:42に示す。
22DA23のH鎖可変領域の塩基配列を配列番号:43、アミノ酸配列を配列番号:44、L鎖可変領域の塩基配列を配列番号:48、アミノ酸配列を配列番号:49に示す。又、22DA23の重鎖CDR1のアミノ酸配列を配列番号:45、重鎖CDR2のアミノ酸配列を配列番号:46、重鎖CDR3のアミノ酸配列を配列番号:47、軽鎖CDR1のアミノ酸配列を配列番号:50、軽鎖CDR2のアミノ酸配列を配列番号:51、軽鎖CDR3のアミノ酸配列を配列番号:52に示す。
22DA24のH鎖可変領域の塩基配列を配列番号:53、アミノ酸配列を配列番号:54、L鎖可変領域の塩基配列を配列番号:58、アミノ酸配列を配列番号:59に示す。又、22DA24の重鎖CDR1のアミノ酸配列を配列番号:55、重鎖CDR2のアミノ酸配列を配列番号:56、重鎖CDR3のアミノ酸配列を配列番号:57、軽鎖CDR1のアミノ酸配列を配列番号:60、軽鎖CDR2のアミノ酸配列を配列番号:61、軽鎖CDR3のアミノ酸配列を配列番号:62に示す。
22SD7のH鎖可変領域の塩基配列を配列番号:63、アミノ酸配列を配列番号:64、L鎖可変領域の塩基配列を配列番号:68、アミノ酸配列を配列番号:69に示す。又、22SD7の重鎖CDR1のアミノ酸配列を配列番号:65、重鎖CDR2のアミノ酸配列を配列番号:66、重鎖CDR3のアミノ酸配列を配列番号:67、軽鎖CDR1のアミノ酸配列を配列番号:70、軽鎖CDR2のアミノ酸配列を配列番号:71、軽鎖CDR3のアミノ酸配列を配列番号:72に示す。
22SD11のH鎖可変領域の塩基配列を配列番号:73、アミノ酸配列を配列番号:74、L鎖可変領域の塩基配列を配列番号:78、アミノ酸配列を配列番号:79に示す。又、22SD11の重鎖CDR1のアミノ酸配列を配列番号:75、重鎖CDR2のアミノ酸配列を配列番号:76、重鎖CDR3のアミノ酸配列を配列番号:77、軽鎖CDR1のアミノ酸配列を配列番号:80、軽鎖CDR2のアミノ酸配列を配列番号:81、軽鎖CDR3のアミノ酸配列を配列番号:82に示す。
22SD48のH鎖可変領域の塩基配列を配列番号:83、アミノ酸配列を配列番号:84、L鎖可変領域の塩基配列を配列番号:88、アミノ酸配列を配列番号:89に示す。又、22SD48の重鎖CDR1のアミノ酸配列を配列番号:85、重鎖CDR2のアミノ酸配列を配列番号:86、重鎖CDR3のアミノ酸配列を配列番号:87、軽鎖CDR1のアミノ酸配列を配列番号:90、軽鎖CDR2のアミノ酸配列を配列番号:91、軽鎖CDR3のアミノ酸配列を配列番号:92に示す。
抗体に毒素等を結合させて細胞内に抗体が標的細胞に結合したのちに細胞内に取り込まれ、コンジュゲートした毒素の作用により標的の細胞を殺すことを作用機序とした抗体医薬の開発のモデルとして、サポリンという毒素の結合された二次抗体、Mab-Zap(Advanced Targeting Systems社製)を用いてLGR7発現細胞に対する殺傷能を評価した。細胞はHA-LGR7を発現させたBaF3細胞を用いた。抗体をウェルあたり100 ng、Mab-Zapをウェルあたり100 ngを加えて3日間37℃ 5% CO2インキュベーターにて保温した後に、生細胞数を生細胞測定試薬SF(ナカライテスク社製)によるWST8アッセイにて解析した。結果を図5に示す。アイソタイプが同じコントロール抗体に比べて、明らかにMab-ZAPとともに作用させた細胞でWST8 assay に値が低く、解析した抗体のいずれにおいても殺細胞効果が確認できた。このことは毒素やラジオアイソトープで標識した抗体が細胞内に取り込まれ、取り込まれた細胞を殺すことができることを示している。
マウスLGR7(塩基配列、配列番号:93、アミノ酸配列、配列番号:94)を発現ベクターに組み込み、BaF3細胞に遺伝子導入して得られた強制発現細胞株HA-mLGR7/BaF3を用いてフローサイトメトリーによりマウスLGR7に対する交差性を調べた。図6に示されるように22DA17、22DA23がマウスのLGR7に対して交差性を示すことが明らかとなった。
Competition FACS 解析によりエピトープを分類した。Biotin Protein Labeling Kit(Roche社)を用いてマニュアルに従って抗体をビオチン化した。Competition FACS解析においては、あらかじめ過剰量の非標識抗体を反応させた後に、ビオチン化した抗体を反応させてさらにFITC標識ストレプトアビジンによりビオチン化された抗体を検出する方法である。同じエピトープを認識する抗体の場合には非標識抗体がエピトープをマスクすることによりビオチン化抗体が抗原にアクセスできず、FACS解析におけるピークが左側にシフトする。同じ抗体で非標識、ビオチン化抗体の順で反応させた場合には競合がかかるためにFITC標識抗マウス抗体を作用させたときに比べてシフトが左側に移動する。一方、違うエピトープを認識する抗体の場合には非標識抗体と競合せずに結合できるため左側へのシフトが少ない。いくつかの抗体をビオチン化して競合アッセイを実施したが、そのうちの一部を図7に示す。ビオチン化した抗体Bio-22DA17、Bio-22DA22を用いたcompetition FACS 解析の結果、22DA12、22DA22は他の抗体と違うエピトープを認識する抗体であることが明らかとなった。
抗体のADCC活性を増強する方法として、抗体の糖鎖を改変する方法が知られている。WO2006/067913等では、フコーストランスポーター遺伝子をノックアウトしたCHO細胞(CHO_FTKO)を用いて、α-1,6コアーフコースを含まない糖鎖を有する抗体を生産することが記載されている。
実施例9のようにしてクローニングした抗ヒトLGR7モノクローナル抗体22DA23の抗体遺伝子はH鎖、L鎖の可変領域をそれぞれPCRで増幅してマウス抗体のH鎖C領域Cγ2a、L鎖C領域Cκと連結してマウスIgG2aキメラ分子として発現できるように哺乳動物細胞用発現ベクターに挿入した。得られたベクターはフコーストランスポーター欠損CHO細胞CHO_FTKO に遺伝子導入してネオマイシン耐性株を樹立した。
RPMI-1640/10% Ultra-low IgG FBS (Invitrogen社)/500μg/mL Geneticine/ペニシリン・ストレプトマイシン存在下で培養し、培養上清からマウスIgG2aキメラ抗体をProteinAカラムにてマニュアルに従って精製した。精製できた抗体22DA23-mIgG2a/FTPKOはマウスxenograft modelでの薬効試験に供された。
精製された22DA23-mIgG2a/FTPKO(FTKODA23)抗体はマウスにおける薬効試験に供された。7週齢のScidメスマウス(日本クレア社)にRMG-1 vivo継代腫瘍、約3mm四方1ピースを皮下に移植し、移植10日後に腫瘍体積、体重で群分けをして実験に供した。RMG-1 vivo継代腫瘍は RMG-1培養細胞を 1e7細胞/bodyで皮下移植したのち、42日後に腫瘍を摘出したものを使用した。マウス6匹を1群としてFTKODA23抗体を 2mg/kg, 10mg/kgで週一回投与した。コントロール群にはPBS(-) を投与した。移植後10日後に初回投与、17日後に2回目投与、24日後に3回目投与、31日後に4回目投与を実施した。腫瘍体積は週2回測定し、4回目の投与後の1週間後に最終測定を行い、腫瘍体積の推移をグラフにしたものを図8に示した。コントロール群と抗体投与群で腫瘍体積の大きさを比較した。TGI(Tumor Growth Inhibition) は10mg/kg の投与群で平均37%、2mg/kgの投与群で平均33%であり、腫瘍縮小効果が認められた。
Claims (24)
- LGR7タンパク質に結合し、かつLGR7タンパク質を発現する細胞に対して細胞増殖阻害活性を有する抗体。
- 細胞増殖阻害活性が細胞傷害活性である請求項1に記載の抗体。
- 前記細胞傷害活性が抗体依存性細胞傷害活性である請求項2に記載の抗体。
- 前記細胞傷害活性が補体依存性細胞傷害活性である請求項2に記載の抗体。
- 細胞傷害性物質が結合した抗体である請求項1~4いずれかに記載の抗体。
- インターナライズ活性を有する抗体である請求項5に記載の抗体。
- 癌細胞の増殖を抑制する抗体である請求項1から6のいずれかに記載の抗体。
- 前記癌細胞が卵巣癌明細胞である請求項7に記載の抗体。
- 以下(1)から(29)のいずれかに記載の抗体;
(1)CDR1として配列番号:5に記載のアミノ酸配列、CDR2として配列番号:6に記載のアミノ酸配列、およびCDR3として配列番号:7に記載のアミノ酸配列を有するH鎖を含む抗体(22DA6重鎖)、
(2)CDR1として配列番号:10に記載のアミノ酸配列、CDR2として配列番号:11に記載のアミノ酸配列、およびCDR3として配列番号:12に記載のアミノ酸配列を有するL鎖を含む抗体(22DA6軽鎖)、
(3)(1)に記載のH鎖、および(2)に記載のL鎖を含む抗体(22DA6)、
(4)CDR1として配列番号:15に記載のアミノ酸配列、CDR2として配列番号:16に記載のアミノ酸配列、およびCDR3として配列番号:17に記載のアミノ酸配列を有するH鎖を含む抗体(22DA7重鎖)、
(5)CDR1として配列番号:20に記載のアミノ酸配列、CDR2として配列番号:21に記載のアミノ酸配列、およびCDR3として配列番号:22に記載のアミノ酸配列を有するL鎖を含む抗体(22DA7軽鎖)、
(6)(4)に記載のH鎖、および(5)に記載のL鎖を含む抗体(22DA7)、
(7)CDR1として配列番号:25に記載のアミノ酸配列、CDR2として配列番号:26に記載のアミノ酸配列、およびCDR3として配列番号:27に記載のアミノ酸配列を有するH鎖を含む抗体(22DA17重鎖)、
(8)CDR1として配列番号:30に記載のアミノ酸配列、CDR2として配列番号:31に記載のアミノ酸配列、およびCDR3として配列番号:32に記載のアミノ酸配列を有するL鎖を含む抗体(22DA17軽鎖)、
(9)(7)に記載のH鎖、および(8)に記載のL鎖を含む抗体(22DA17)、
(10)CDR1として配列番号:35に記載のアミノ酸配列、CDR2として配列番号:36に記載のアミノ酸配列、およびCDR3として配列番号:37に記載のアミノ酸配列を有するH鎖を含む抗体(22DA22重鎖)、
(11)CDR1として配列番号:40に記載のアミノ酸配列、CDR2として配列番号:41に記載のアミノ酸配列、およびCDR3として配列番号:42に記載のアミノ酸配列を有するL鎖を含む抗体(22DA22軽鎖)、
(12)(10)に記載のH鎖、および(11)に記載のL鎖を含む抗体(22DA22)、
(13)CDR1として配列番号:45に記載のアミノ酸配列、CDR2として配列番号:46に記載のアミノ酸配列、およびCDR3として配列番号:47に記載のアミノ酸配列を有するH鎖を含む抗体(22DA23重鎖)、
(14)CDR1として配列番号:50に記載のアミノ酸配列、CDR2として配列番号:51に記載のアミノ酸配列、およびCDR3として配列番号:52に記載のアミノ酸配列を有するL鎖を含む抗体(22DA23軽鎖)、
(15)(13)に記載のH鎖、および(14)に記載のL鎖を含む抗体(22DA23)、
(16)CDR1として配列番号:55に記載のアミノ酸配列、CDR2として配列番号:56に記載のアミノ酸配列、およびCDR3として配列番号:57に記載のアミノ酸配列を有するH鎖を含む抗体(22DA24重鎖)、
(17)CDR1として配列番号:60に記載のアミノ酸配列、CDR2として配列番号:61に記載のアミノ酸配列、およびCDR3として配列番号:62に記載のアミノ酸配列を有するL鎖を含む抗体(22DA24軽鎖)、
(18)(16)に記載のH鎖、および(17)に記載のL鎖を含む抗体(22DA24)、
(19)CDR1として配列番号:65に記載のアミノ酸配列、CDR2として配列番号:66に記載のアミノ酸配列、およびCDR3として配列番号:67に記載のアミノ酸配列を有するH鎖を含む抗体(22SD7重鎖)、
(20)CDR1として配列番号:70に記載のアミノ酸配列、CDR2として配列番号:71に記載のアミノ酸配列、およびCDR3として配列番号:72に記載のアミノ酸配列を有するL鎖を含む抗体(22SD7軽鎖)、
(21)(19)に記載のH鎖、および(20)に記載のL鎖を含む抗体(22SD7)、
(22)CDR1として配列番号:75に記載のアミノ酸配列、CDR2として配列番号:76に記載のアミノ酸配列、およびCDR3として配列番号:77に記載のアミノ酸配列を有するH鎖を含む抗体(22SD11重鎖)、
(23)CDR1として配列番号:80に記載のアミノ酸配列、CDR2として配列番号:81に記載のアミノ酸配列、およびCDR3として配列番号:82に記載のアミノ酸配列を有するL鎖を含む抗体(22SD11軽鎖)、
(24)(22)に記載のH鎖、および(23)に記載のL鎖を含む抗体(22SD11)、
(25)CDR1として配列番号:85に記載のアミノ酸配列、CDR2として配列番号:86に記載のアミノ酸配列、およびCDR3として配列番号:87に記載のアミノ酸配列を有するH鎖を含む抗体(22SD48重鎖)、
(26)CDR1として配列番号:90に記載のアミノ酸配列、CDR2として配列番号:91に記載のアミノ酸配列、およびCDR3として配列番号:92に記載のアミノ酸配列を有するL鎖を含む抗体(22SD48軽鎖)、
(27)(25)に記載のH鎖、および(26)に記載のL鎖を含む抗体(22SD48)、
(28)(1)~(27)いずれかに記載の抗体と同等の活性を有する抗体、
(29)(1)~(27)いずれかに記載の抗体が認識するエピトープと同一のエピトープを認識する抗体。 - ヒト定常領域を有する抗体である請求項1~9のいずれかに記載の抗体。
- キメラ抗体、ヒト化抗体またはヒト抗体である請求項10に記載の抗体。
- フコースが欠損した抗体である請求項1~11のいずれかに記載の抗体。
- 請求項1から12のいずれかに記載の抗体を有効成分として含有する医薬組成物。
- 請求項1から12のいずれかに記載の抗体を有効成分として含有する細胞増殖抑制剤。
- 請求項1から12のいずれかに記載の抗体を有効成分として含有する抗癌剤。
- 治療対象となる癌が卵巣癌である、請求項15に記載の抗癌剤。
- 前記卵巣癌が明細胞腺癌である請求項16に記載の抗癌剤。
- LGR7タンパク質またはLGR7タンパク質をコードする遺伝子を検出することを特徴とする癌の診断方法。
- LGR7タンパク質を検出することを特徴とする癌の診断方法。
- LGR7タンパク質の検出がLGR7タンパク質に結合する抗体を用いて行なわれる請求項19に記載の診断方法。
- 以下の工程を含む癌の診断方法;
(a) 被検者から採取された試料を提供する工程、
(b) (a)の試料に含まれるLGR7タンパク質を、LGR7タンパク質に結合する抗体を用いて検出する工程。 - 以下の工程を含む癌の診断方法;
(a) LGR7タンパク質への結合活性を有し、かつ放射性同位元素で標識された抗体を被検者に投与する工程、
(b) 前記放射性同位元素の集積を検出する工程。 - 診断対象となる癌が卵巣癌である請求項18から22のいずれかに記載の診断方法。
- 前記卵巣癌が明細胞腺癌である請求項23に記載の診断方法。
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG2011047768A SG172427A1 (en) | 2008-12-26 | 2009-12-25 | Diagnosis and treatment of cancer using anti-lgr7 antibody |
CN2009801576612A CN102395603A (zh) | 2008-12-26 | 2009-12-25 | 使用抗lgr7抗体的癌症的诊断和治疗 |
EP09834988.9A EP2377891B1 (en) | 2008-12-26 | 2009-12-25 | Diagnosis and treatment of cancer using anti-lgr7 antibody |
JP2010544139A JP5801557B2 (ja) | 2008-12-26 | 2009-12-25 | 抗lgr7抗体を用いる癌の診断および治療 |
MX2011006908A MX2011006908A (es) | 2008-12-26 | 2009-12-25 | Diagnosis y tratamiento del cancer utilizando el anticuerpo anti-lgr7. |
BRPI0923652A BRPI0923652A2 (pt) | 2008-12-26 | 2009-12-25 | diagnóstico e tratamento de câncer usando anticorpo anti-lgr7 |
US13/140,351 US20120014870A1 (en) | 2008-12-26 | 2009-12-25 | Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody |
RU2011131071/10A RU2011131071A (ru) | 2008-12-26 | 2009-12-25 | Диагностика и лечение рака с помощью антитела против lgr7 |
CA2748990A CA2748990A1 (en) | 2008-12-26 | 2009-12-25 | Diagnosis and treatment of cancer using anti-lgr7 antibody |
AU2009331178A AU2009331178A1 (en) | 2008-12-26 | 2009-12-25 | Diagnosis and treatment of cancer using anti-LGR7 antibody |
US16/782,728 US20200157231A1 (en) | 2008-12-26 | 2020-02-05 | Diagnosis and treatment of cancer using anti-lgr7 antibody |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008333149 | 2008-12-26 | ||
JP2008-333149 | 2008-12-26 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/140,351 A-371-Of-International US20120014870A1 (en) | 2008-12-26 | 2009-12-25 | Diagnosis and Treatment of Cancer Using Anti-LGR7 Antibody |
US16/782,728 Division US20200157231A1 (en) | 2008-12-26 | 2020-02-05 | Diagnosis and treatment of cancer using anti-lgr7 antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010074192A1 true WO2010074192A1 (ja) | 2010-07-01 |
Family
ID=42287797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/071524 WO2010074192A1 (ja) | 2008-12-26 | 2009-12-25 | 抗lgr7抗体を用いる癌の診断および治療 |
Country Status (12)
Country | Link |
---|---|
US (2) | US20120014870A1 (ja) |
EP (1) | EP2377891B1 (ja) |
JP (1) | JP5801557B2 (ja) |
KR (1) | KR20110099762A (ja) |
CN (1) | CN102395603A (ja) |
AU (1) | AU2009331178A1 (ja) |
BR (1) | BRPI0923652A2 (ja) |
CA (1) | CA2748990A1 (ja) |
MX (1) | MX2011006908A (ja) |
RU (1) | RU2011131071A (ja) |
SG (1) | SG172427A1 (ja) |
WO (1) | WO2010074192A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9403913B2 (en) * | 2014-09-16 | 2016-08-02 | Ovascience, Inc. | Anti-VASA antibodies, and methods of production and use thereof |
JP2022507693A (ja) * | 2018-11-20 | 2022-01-18 | ウニベルジテート ハイデルベルク | 心不全の治療及び予防における使用のためのリラキシン受容体1 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2677367T3 (es) * | 2011-06-22 | 2018-08-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticuerpos anti-Axl y usos de los mismos |
CN102636655B (zh) * | 2012-05-10 | 2014-07-23 | 苏州大学附属第一医院 | 一种荧光原位微量淋巴毒检测方法和试剂盒 |
US10711153B2 (en) * | 2013-09-27 | 2020-07-14 | Stora Enso Oyj | Composition comprising lignin and epoxy compound for coating and method for the manufacturing thereof and use thereof |
US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11332531B2 (en) | 2016-12-23 | 2022-05-17 | Remd Biotherapeutics, Inc. | Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1) |
CN114230666B (zh) * | 2021-12-20 | 2022-09-02 | 南京诺唯赞生物科技股份有限公司 | 一种t7 rna聚合酶的单克隆抗体及其制备方法 |
Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
JPH0159878B2 (ja) | 1982-05-21 | 1989-12-20 | Yunibaashitei Obu Karifuorunia | |
EP0404097A2 (de) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994011523A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Fully impaired consensus kozac sequences for mammalian expression |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1999048921A1 (en) | 1998-03-26 | 1999-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Novel mammalian g-protein coupled receptors having extracellular leucine rich repeat regions |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO1999056129A1 (en) * | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
WO2002079255A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
WO2003016487A2 (en) | 2001-08-17 | 2003-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian relaxin receptors |
WO2003093827A2 (en) | 2002-05-02 | 2003-11-13 | Bayer Healthcare Ag | Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7) |
WO2003104453A1 (ja) | 2002-06-05 | 2003-12-18 | 中外製薬株式会社 | 抗体作製方法 |
US20050107595A1 (en) | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2005107396A2 (en) | 2004-04-30 | 2005-11-17 | Chiron Corporation | Novel compositions and methods in cancer |
WO2006067913A1 (ja) | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
WO2008093688A1 (ja) | 2007-01-30 | 2008-08-07 | Forerunner Pharma Research Co., Ltd. | キメラFcγレセプター及び該レセプターを用いたADCC活性測定方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL155250A0 (en) * | 2000-10-04 | 2003-11-23 | Molecular Medicine Res Inst | Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
-
2009
- 2009-12-25 KR KR1020117017401A patent/KR20110099762A/ko not_active Application Discontinuation
- 2009-12-25 MX MX2011006908A patent/MX2011006908A/es unknown
- 2009-12-25 CA CA2748990A patent/CA2748990A1/en not_active Abandoned
- 2009-12-25 EP EP09834988.9A patent/EP2377891B1/en not_active Not-in-force
- 2009-12-25 AU AU2009331178A patent/AU2009331178A1/en not_active Abandoned
- 2009-12-25 SG SG2011047768A patent/SG172427A1/en unknown
- 2009-12-25 BR BRPI0923652A patent/BRPI0923652A2/pt not_active IP Right Cessation
- 2009-12-25 CN CN2009801576612A patent/CN102395603A/zh not_active Withdrawn
- 2009-12-25 RU RU2011131071/10A patent/RU2011131071A/ru unknown
- 2009-12-25 WO PCT/JP2009/071524 patent/WO2010074192A1/ja active Application Filing
- 2009-12-25 JP JP2010544139A patent/JP5801557B2/ja not_active Expired - Fee Related
- 2009-12-25 US US13/140,351 patent/US20120014870A1/en not_active Abandoned
-
2020
- 2020-02-05 US US16/782,728 patent/US20200157231A1/en not_active Abandoned
Patent Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0159878B2 (ja) | 1982-05-21 | 1989-12-20 | Yunibaashitei Obu Karifuorunia | |
EP0239400A2 (en) | 1986-03-27 | 1987-09-30 | Medical Research Council | Recombinant antibodies and methods for their production |
EP0404097A2 (de) | 1989-06-22 | 1990-12-27 | BEHRINGWERKE Aktiengesellschaft | Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung |
WO1992001047A1 (en) | 1990-07-10 | 1992-01-23 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992020791A1 (en) | 1990-07-10 | 1992-11-26 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993006213A1 (en) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1993019172A1 (en) | 1992-03-24 | 1993-09-30 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
WO1994011523A2 (en) | 1992-11-13 | 1994-05-26 | Idec Pharmaceuticals Corporation | Fully impaired consensus kozac sequences for mammalian expression |
WO1994025585A1 (en) | 1993-04-26 | 1994-11-10 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1995001438A1 (en) | 1993-06-30 | 1995-01-12 | Medical Research Council | Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof |
WO1995015388A1 (en) | 1993-12-03 | 1995-06-08 | Medical Research Council | Recombinant binding proteins and peptides |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
WO1996033735A1 (en) | 1995-04-27 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
WO1999048921A1 (en) | 1998-03-26 | 1999-09-30 | The Board Of Trustees Of The Leland Stanford Junior University | Novel mammalian g-protein coupled receptors having extracellular leucine rich repeat regions |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
WO1999056129A1 (en) * | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
WO2000061739A1 (en) | 1999-04-09 | 2000-10-19 | Kyowa Hakko Kogyo Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2002031140A1 (fr) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kogyo Co., Ltd. | Cellules produisant des compositions d'anticorps |
WO2002079255A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
US20050107595A1 (en) | 2001-06-20 | 2005-05-19 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
WO2003016487A2 (en) | 2001-08-17 | 2003-02-27 | The Board Of Trustees Of The Leland Stanford Junior University | Mammalian relaxin receptors |
WO2003093827A2 (en) | 2002-05-02 | 2003-11-13 | Bayer Healthcare Ag | Diagnostics and drug screening for diseases associated with leucine-rich repeat-containing g-protein coupled receptor 7 (lgr7) |
WO2003104453A1 (ja) | 2002-06-05 | 2003-12-18 | 中外製薬株式会社 | 抗体作製方法 |
WO2005107396A2 (en) | 2004-04-30 | 2005-11-17 | Chiron Corporation | Novel compositions and methods in cancer |
WO2006067913A1 (ja) | 2004-12-22 | 2006-06-29 | Chugai Seiyaku Kabushiki Kaisha | フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法 |
WO2008093688A1 (ja) | 2007-01-30 | 2008-08-07 | Forerunner Pharma Research Co., Ltd. | キメラFcγレセプター及び該レセプターを用いたADCC活性測定方法 |
Non-Patent Citations (80)
Title |
---|
"Current Protocols in Immunology", 1993, JOHN WILEY & SONS, INC. |
"Remington's Pharmaceutical Science", MARK PUBLISHING COMPANY |
BATHGATE RA. ET AL., PHARMACOL REV, vol. 58, 2006, pages 7 - 31 |
BELYAVSKY, A. ET AL., NUCLEIC ACIDS RES., vol. 17, 1989, pages 2919 - 2932 |
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043 |
BETTER, M., HORWITZ, A. H., METHODS ENZYMOL., vol. 178, 1989, pages 476 - 496 |
BETTER, M., HORWITZ, A. H., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 476 - 496 |
BIRD, R. E. ET AL., TIBTECH, vol. 9, 1991, pages 132 - 137 |
BIRD, R. E., WALKER, B. W., TRENDS BIOTECHNOL., vol. 9, 1991, pages 132 - 137 |
BOLOGNESI A. ET AL., CLIN. EXP. IMMUNOL., vol. 89, 1992, pages 341 - 346 |
CASELLAS P. ET AL., EUR. J. BIOCHEM., vol. 176, 1988, pages 581 - 588 |
CELLULAR & MOLECULAR IMMUNOLOGY, vol. 3, 2006, pages 439 - 443 |
CHIRGWIN, J. M. ET AL., BIOCHEMISTRY, vol. 18, 1979, pages 5294 - 5299 |
CHOMCZYNSKI, P. ET AL., ANAL. BIOCHEM., vol. 162, 1987, pages 156 - 159 |
CO, M. S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976 |
CUMBER A. J. ET AL., J. IMMUNOL. METHODS, vol. 135, 1990, pages 15 - 24 |
CURRENT TOPICS IN MICROBIOLOGY AND IMMUNOLOGY, vol. 81, 1978, pages 1 - 7 |
DALBADIE- MCFARLAND, G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 - 6413 |
DE ST. GROTH, S. F. ET AL., J. IMMUNOL. METHODS, vol. 35, 1980, pages 1 - 21 |
EBERT, K. M. ET AL., BIO/TECHNOLOGY, vol. 12, 1994, pages 699 - 702 |
ED HARLOW, DAVID LANE: "Antibodies A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
ED HARLOW, DAVID LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY |
ENOMOTO T, PROCEEDINGS OF ASCO, 2003, pages 1797 |
FASEB J, vol. 6, 1992, pages 2422 - 2427 |
FROHMAN, M. A. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 8998 - 9002 |
FULTON R. J. ET AL., J. BIOL. CHEM., vol. 261, 1986, pages 5314 - 5319 |
GALFRE, G. ET AL., NATURE, vol. 277, 1979, pages 131 - 133 |
GHEEITE V. ET AL., J. IMMUNOL. METHODS, vol. 142, 1991, pages 223 - 230 |
HALLS M. L. ET AL., BRITISH JOURNAL OF PHARMACOLOGY, vol. 150, 2007, pages 677 - 691 |
HASHIMOTO-GOTOH, T. ET AL., GENE, vol. 152, 1995, pages 271 - 275 |
HOLLINGER P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448 |
HOMBACH-KLONISCH S. ET AL., AMERICAN JOURNAL OF PATHOLOGY, vol. 169, 2006, pages 617 - 632 |
HSU, S. Y. ET AL., MOLEC. ENDOCR., vol. 14, 2000, pages 1257 - 1271 |
HSUEH A. J. W. ET AL., JOURNAL OF ENDOCRINOLOGY, vol. 187, 2005, pages 333 - 338 |
HUDSON ET AL., J. IMMUNOL. METHODS, vol. 231, 1999, pages 177 - 189 |
HUSTON, J. S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883 |
IVELL, R. ET AL.: "Immunoexpression of the relaxin receptor LGR7 inbreast and uterine tissues of humans and primates.", REPROD. BIOL. ENDOCRINOL., vol. 1, no. 114, 24 November 2003 (2003-11-24), pages 1/13 - 13/13, XP021009265 * |
J. IMMUNOL., vol. 123, 1979, pages 1548 - 1550 |
J. MOL. BIOL., vol. 222, 1991, pages 581 - 597 |
KEM A. ET AL., ENDOCRINOLOGY, vol. 148, 2007, pages 1181 - 1194 |
KOHLER. G., MILSTEIN, C., EUR. J. IMMUNOL., vol. 6, 1976, pages 511 - 519 |
KOHLER. G., MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46 |
KRAMER W, FRITZ HJ, METHODS. ENZYMOL., vol. 154, 1987, pages 350 - 367 |
KRAMER, W. ET AL., NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456 |
KRISTIANSEN K., PHARMACOLOGY & THERAPEUTICS, vol. 103, 2004, pages 21 - 80 |
KUNKEL, METHODS ENZYMOL., vol. 85, 1988, pages 2763 - 2766 |
KUNKEL, TA, PROC. NATL. ACAD. SCI. USA., vol. 82, 1985, pages 488 - 492 |
LAMOYI, E., METHODS ENZYMOL., vol. 121, 1986, pages 652 - 663 |
LAMOYI, E., METHODS IN ENZYMOLOGY, vol. 121, 1989, pages 652 - 663 |
LANGONE J. J. ET AL., METHODS IN ENZYMOLOGY, vol. 93, 1983, pages 307 - 308 |
LEI, S. P. ET AL., J. BACTERIOL., vol. 169, 1987, pages 4379 |
MARGULIES. D.H. ET AL., CELL, vol. 8, 1976, pages 405 - 415 |
MARK, D. F. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 5666 |
METHODS, vol. 31, 2003, pages 232 - 242 |
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322 |
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108 |
NATURE MEDICINE, vol. 2, 1996, pages 350 - 353 |
NIHON SANFUJINKA GAKKAI-SHI, vol. 57, no. 11, 2005, pages 1711 |
PLUCKTHUN, A., SKERRA, A., METHODS ENZYMOL., vol. 178, 1989, pages 497 - 515 |
PLUECKTHUN, A., SKERRA, A., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 476 - 496 |
PROTEIN ENGINEERING, vol. 9, no. 3, 1996, pages 299 - 305 |
ROUSSEAUX, J. ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 663 - 669 |
ROUSSEAUX, J. ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1989, pages 663 - 669 |
SAMBROOK J ET AL.: "Molecular Cloning", 1989, COLD SPRING HARBOR LAB. PRESS |
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856 |
SHULMAN, M. ET AL., NATURE, vol. 276, 1978, pages 269 - 270 |
SIVAM G. ET AL., CANCER RES., vol. 47, 1987, pages 3169 - 3173 |
STIRPE F., BARBIERI L., FEBS LETTER, vol. 195, 1986, pages 1 - 8 |
SUGIYAMA T ET AL., CANCER, vol. 88, 2000, pages 2584 |
THORPE P. E. ET AL., CANCER RES., vol. 47, 1987, pages 5924 - 5931 |
TROWBRIDGE, I. S., J. EXP. MED., vol. 148, 1978, pages 313 - 323 |
VAN DER WESTHUIZEN, E. T. ET AL., CURRENT DRUG TARGETS, vol. 8, 2007, pages 91 - 104 |
VANDAMME, A. M. ET AL., EUR. J. BIOCHEM., vol. 192, 1990, pages 767 - 775 |
VINALL R. L. ET AL., ONCOGENE, vol. 25, 2006, pages 2082 - 2093 |
WANG, A. ET AL., SCIENCE, vol. 224, pages 1431 - 1433 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
WAWRZYNCZAK E. J. ET AL., BR. J. CANCER, vol. 66, 1992, pages 361 - 366 |
WAWRZYNCZAK E. J. ET AL., CANCER RES., vol. 50, 1990, pages 7519 - 7562 |
ZOLLER, M. J., SMITH, M., NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487 - 6500 |
ZOLLER, MJ, SMITH, M., METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9403913B2 (en) * | 2014-09-16 | 2016-08-02 | Ovascience, Inc. | Anti-VASA antibodies, and methods of production and use thereof |
US9567404B2 (en) | 2014-09-16 | 2017-02-14 | Ovascience, Inc. | Anti-vasa antibodies, and methods of production and use thereof |
JP2022507693A (ja) * | 2018-11-20 | 2022-01-18 | ウニベルジテート ハイデルベルク | 心不全の治療及び予防における使用のためのリラキシン受容体1 |
JP7541003B2 (ja) | 2018-11-20 | 2024-08-27 | ウニベルジテート ハイデルベルク | 心不全の治療及び予防における使用のためのリラキシン受容体1 |
Also Published As
Publication number | Publication date |
---|---|
EP2377891A1 (en) | 2011-10-19 |
EP2377891A4 (en) | 2012-08-29 |
JPWO2010074192A1 (ja) | 2012-06-21 |
MX2011006908A (es) | 2011-10-06 |
CN102395603A (zh) | 2012-03-28 |
US20200157231A1 (en) | 2020-05-21 |
BRPI0923652A2 (pt) | 2016-10-18 |
AU2009331178A1 (en) | 2011-08-11 |
EP2377891B1 (en) | 2018-11-21 |
RU2011131071A (ru) | 2013-02-10 |
JP5801557B2 (ja) | 2015-10-28 |
SG172427A1 (en) | 2011-07-28 |
CA2748990A1 (en) | 2010-07-01 |
KR20110099762A (ko) | 2011-09-08 |
US20120014870A1 (en) | 2012-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5986621B2 (ja) | 抗gpr49抗体を用いる癌の診断および治療 | |
JP6162864B2 (ja) | 抗Desmoglein3抗体を用いる癌の診断および治療 | |
JP5918540B2 (ja) | 抗dll3抗体 | |
JP6104794B2 (ja) | 抗itm2a抗体を用いる癌の診断および治療 | |
US20200157231A1 (en) | Diagnosis and treatment of cancer using anti-lgr7 antibody | |
JP6009733B2 (ja) | 抗tm4sf20抗体を用いた癌の診断と治療 | |
WO2011105573A1 (ja) | 抗icam3抗体およびその用途 | |
JP5746018B2 (ja) | 抗tmprss11e抗体を用いた癌の診断と治療 | |
MX2011006895A (es) | Pasta de papel de fibra mejorada. | |
JP5618172B2 (ja) | 抗prg−3抗体を用いる癌の診断および治療 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980157661.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09834988 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010544139 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4660/DELNP/2011 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2011/006908 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2748990 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009331178 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009834988 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 20117017401 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011131071 Country of ref document: RU |
|
ENP | Entry into the national phase |
Ref document number: 2009331178 Country of ref document: AU Date of ref document: 20091225 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13140351 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: PI0923652 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: PI0923652 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110624 |